




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 471/04, A61K 31/435, C07D 498/04, 491/048, 513/04, 495/04 // (C07D 471/04, 221:00, 209:00) (C07D 471/04, 235:00, 221:00)		A1	(11) International Publication Number: WO 95/04734
			(43) International Publication Date: 16 February 1995 (16.02.95)
(21) International Application Number: PCT/EP94/02325			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).
(22) International Filing Date: 14 July 1994 (14.07.94)			
(30) Priority Data: MI93A001788 6 August 1993 (06.08.93) IT MI94A000202 4 February 1994 (04.02.94) IT			
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM FARMACEUTICI S.p.A. [IT/IT]; Via Zambelli, I-20021 Baranzate (IT).		Published	With international search report.
(72) Inventors; and			
(75) Inventors/Applicants (for US only): DONDIO, Giulio [IT/IT]; SmithKline Beecham Farmaceutici S.p.A., Via Zambelli, I-20021 Baranzate (IT). RONZONI, Silvano [IT/IT]; SmithKline Beecham Farmaceutici S.p.A., Via Zambelli, I-20021 Baranzate (IT).			
(74) Agent: RUSSELL, Brian, John; SmithKline Beecham, Corporate Intellectual Property, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).			

(54) Title: HYDROISOQUINOLINE DERIVATIVES

(57) Abstract

Tricyclic derivatives of octahydroisoquinoline of formula (I), wherein n is zero or 1 and if n is zero, one of X or Y is NH, oxygen or sulphur, and the other is NH, CH or a R₄- or R₅-substituted carbon atom; if n is 1, then X and Y are both nitrogen, or one of them is nitrogen and the other is CH or an R₄- or R₅-substituted carbon atom, have selective receptor agonist or antagonist activity, and are of potential therapeutic utility as analgesics or immunomodulating and/or cardiovascular agents.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HYDROISOQUINOLINE DERIVATIVES

This invention is concerned with novel hydroisoquinoline derivatives, processes for their preparation, and their use in medicine.

5 The presence of at least three populations of opioid receptors (μ , δ and kappa) is now well established and documented and all three appear to be present in the central and peripheral nervous system of many species, including man (Lord J.A.H. et al., Nature 1977, 267, 495).


10 Activation of all 3 opioid receptor subtypes can lead to antinociception in animal models. In particular, studies with peptidic δ agonists have indicated that activation of the δ receptor produces antinociceptive activity in rodents and primates, and can induce clinical analgesia in man (Yaksh T.L. and Onofrio, B.M., Lancet 1983, 1386). Some experiments suggest that these δ analgesics may also lack the usual side-effects associated with μ and kappa receptor activation (Galligan et al, J. 15 Pharm. Exp. Ther. 1984, 229, 641).

Octahydroisoquinoline derivatives having selectivity for the δ receptor have already been described. All the known derivatives are characterized by bicyclic heterocycle systems condensed at the isoquinoline ring. For example, octahydroisoquinoline derivatives are disclosed in EP-A-0,485,636 (Toray Ind.); JP-20 A-4,368,384, (Toray Ind.), whereas quinoline- and quinoxaline-octahydroisoquinoline derivatives are disclosed in JP-A- 6,275,288 (Toray Ind.). In WO 93/01186 (Dr. Lo Zambeletti), indole-, benzofuro- or quinolino-octahydroisoquinoline derivatives are disclosed.

25 A structural characteristic of the compounds disclosed in the documents mentioned above, therefore, is the presence of a condensed tetracyclic system.

30 A novel class of tricyclic derivatives of octahydroisoquinoline condensed with monocyclic heterocycles has now been found, characterised by a selective δ receptor agonistic or antagonistic activity. These derivatives are therefore of potential therapeutic utility as analgesics or immunomodulating and/or cardiovascular agents.

According to the present invention, there is provided a compound, or solvate or salt thereof, of formula (I):




wherein:

R is hydrogen or a straight or branched C₁-C₅ alkyl, C₃-C₇ cycloalkyl, C₄-C₆ cycloalkylalkyl, C₃-C₅ alkenyl, aryl, aralkyl or furan-2-yl-alkyl;

5 R₁ and R₂, which can be the same or different, are each hydrogen, hydroxy, C₁-C₃ alkoxy, preferably methoxy, halogen, SH, C₁-C₄-alkylthio, NHR₆, NR₆R₇, NHCOR₆, NHSO₂R₆, wherein R₆ and R₇, which are the same or different, are hydrogen or C₁-C₆ alkyl;

R₃ is hydrogen, hydroxy or C₁-C₃ alkoxy, preferably methoxy;




10

(R₁ and R₂ having the meanings defined above) or a -C(Z)-R₈ group, in which Z is oxygen or sulphur, and R₈ is C₁-C₁₈-alkyl, C₁-C₁₈-alkoxy or NR₉R₁₀, wherein R₉ and R₁₀, which may be the same or different, are hydrogen, straight or branched C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₆ cycloalkylalkyl, C₃-C₆ alkenyl, aryl, aralkyl


15 or an optionally substituted heterocyclic ring or, taken together with the nitrogen atom which they are linked to, they form an alkylene chain having from 2 to 5 carbon atoms, optionally interrupted by an oxygen or nitrogen atom;

or R₄ is a group



20 in which R₁₁ and R₁₂ are the same as R₉ and R₁₀ respectively, and Z is as defined above;

R₅ is hydrogen, C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, trifluoromethyl or is a



25 (R₁ and R₂ having the meanings defined above);

n is zero or 1;

if n is zero, one of X or Y is NH, oxygen or sulphur, and the other is NH, CH or a R₄- or R₅-substituted carbon atom; if n is 1, then X and Y are both nitrogen, or one of them is nitrogen and the other is CH or a R₄- or R₅-substituted carbon atom.

When R is aryl, it is preferably phenyl, and when it is aralkyl, it is preferably phenyl-C₁-C₆ alkyl.

Examples of R are hydrogen, methyl, ethyl, cyclopropylmethyl, propyl, 2-furylmethyl and 2-phenylethyl.

5 Examples of R₁ and R₂ are hydrogen, hydroxy, methoxy, chlorine, bromine, fluorine, SH, methylthio, amino, methylamino, ethylamino, dimethylamino, diethylamino, diisopropylamino, methylisopropylamino, acetylamino and sulfonylamino, at any position of the ring.

10 Examples of R₆ and R₇ groups are hydrogen, methyl, ethyl, n-propyl, isopropyl and n-butyl.

Examples of R₈ groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-heptyl, n-undecyl, n-tridecyl, n-heptadecyl, methoxy, ethoxy, propoxy, isopropoxy, hexyloxy, decyloxy, amino, methylamino, dimethylamino, diethylamino.

15 Examples of R₄ are ethoxycarbonyl, i-butyloxycarbonyl, aminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, di-n-propylaminocarbonyl, di-i-propylaminocarbonyl, pyrrolidinocarbonyl, benzylaminocarbonyl, phenylaminocarbonyl, morpholinocarbonyl, N-ethyl-N-i-isopropylaminocarbonyl, diethylaminothiocarbonyl, phenyl.

20 Examples of R₅ groups are hydrogen, methyl, ethyl, propyl, butyl, hexyl, octyl, decyl, dodecyl, octadecyl, allyl, trifluoromethyl and phenyl.

Examples of R₉ and R₁₀ are hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, allyl, benzyl, phenyl, pyrrole, furan and pyridine.

Examples of the group



are acetamido, propionamido, isobutyramido and benzamido.

A first group of preferred compounds of formula (I) is one in which n is zero, X is NH and Y is CH or a R₄- or R₅-substituted carbon atom.

30 A second group of preferred compounds of formula (I) is one in which n is zero, X is CH or a R₄- or R₅-substituted carbon atom and Y is NH.

A third group of preferred compounds of formula (I) is one in which n is zero, X is a sulphur or oxygen atom and Y is CH or a R₄- or R₅-substituted carbon atom.


35 A fourth group of preferred compounds of formula (I) is one in which n is zero, X is CH or a R₄- or R₅-substituted carbon atom, and Y is an oxygen or sulphur atom.

A fifth group of preferred compounds of formula (I) is one in which n is 1, X is a nitrogen atom and Y is CH or a R₄- or R₅-substituted carbon atom.

A sixth group of preferred compounds of formula (I) is one in which n is 1, X

is CH or a R₄- or R₅-substituted carbon atom and Y is a nitrogen atom.

Particularly preferred compounds of formula (I) are those in which R₅ is hydrogen and R₄ is a



5 wherein R₈ is a C₁-C₆ alkyl, C₁-C₄ alkoxy or -NR₆R₇ group, R₆ or R₇ being as defined above.

Most preferred compounds are those in which R₈ is a -NR₆R₇ group and Z is oxygen.

10 The compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, *inter alia*, of a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.

15 A substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) or its salt or solvate.

One preferred pharmaceutically acceptable form is the crystalline form, including such form in a pharmaceutical composition. In the case of salts and solvates the additional ionic and solvent moieties must also be non-toxic.

20 Examples of pharmaceutically acceptable salts of a compound of formula (I) include acid addition salts with the conventional pharmaceutical acids, for example, maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic and methanesulphonic acids.


25 Examples of pharmaceutically acceptable solvates of a compound of formula (I) include hydrates.

The compounds of formula (I) may exist as cis or trans isomers, and the invention extends to both such forms as well as to their single enantiomers and to mixtures thereof, including racemates.

30 The invention also provides processes for the preparation of the compounds of formula (I).

Compounds of formula (I) in which n is zero, X is NH and Y is a R₅-substituted carbon atom, are obtained by cyclization of ketones of formula (II) (J. Org. Chem. 54, 1442 (1989)) with hydrazones of formula (III), working in the presence of metal zinc in acetic buffer, analogously to the method described in 35 Khimiya Geterot. Soed. 342-4, 1972; see scheme 1:


Scheme 1



5

Compounds of formula (I) in which n is zero, X is NH and Y is a R_4 -substituted carbon atom, are obtained by cyclization of bromoketones of formula (IV) (which may be obtained from ketones (II) by reaction with cupric bromide in chloroform, analogously to the method described in J. Org. Chem. **29**, 3459 (1964)), 10 with ketones (V) in the presence of ammonia, analogously to the method described in Can. J. Chem. **48**, 1689 (1970); see scheme 2:


Scheme 2



15

Compounds of formula (I) in which n is zero, X is oxygen and Y is a R_5 -substituted carbon atom, are obtained by cyclization of ketones (II) with α -haloketones (preferably α -chloroketones) (VI), in the presence of bases, analogously 20 to the method described in J. Org. Chem. **49**, 2317 (1984); see scheme 3:


Scheme 3



Compounds of formula (I) in which n is zero, X is oxygen and Y is a R₄-substituted carbon atom, are obtained by cyclization of bromoketones (IV) with ketones (V) in ethanol, in the presence of a base (suitably sodium ethoxide) analogously to the method described in J. Chem. Soc. Perkin I, 2372, (1972); see scheme 4:

10


Scheme 4



Compounds of formula (I) in which n is zero, X is sulphur and Y is a R₅-substituted carbon atom, are obtained by reacting β -diketones (VII) (which can be prepared by Claisen condensation from ketones (II) and esters of formula R₅-COOEt; J. Am. Chem. Soc. 67, 1510, 1945) with mercaptans (VIII) in the presence of hydrochloric acid, analogously to the method described in DE 1.088.507 (C.A. 56, 456 (1962)); see scheme 5:

20


Scheme 5



Compounds of formula (I) in which n is zero, Y is sulphur and X is a R₄-substituted carbon atom are obtained by reacting α -mercaptopketones (IX) (which are prepared starting from bromoketones (IV) and H₂S in potassium hydroxide (J. Am. Chem. Soc. 107, 4175 (1985)) with acetylene derivatives (X), in aprotic solvents (preferably dimethylsulfoxide) in the presence of bases such as potassium tert-butoxide, as described in Chem. Ber. 97, 2109 (1964); see scheme 6:

5


Scheme 6



Compounds of formula (I) in which n is 1, X is a nitrogen atom and Y is CH are obtained by reacting hydroxymethyleneketones (XI) (which can be prepared from ketones (II) by condensation with ethyl formate in the presence of a base; Org. Synth. 15 Coll. Vol. 4, 536, 1963) with enamine (XII), analogously to the method described in J. Ind. Chem. Soc. 12, 289 (1935); see scheme 7:

15


Scheme 7



Compounds of formula (I) in which n is 1 and both X and Y are nitrogen atoms are obtained according to the invention by reacting α -hydroxyiminoketones (XIII) (which can be prepared by reacting ketones (II) with isoamyl nitrite and potassium tert-butoxide; J. Med. Chem. 34, 1715, 1991) with ethanediamine (XIV) and subsequent aromatization of the intermediate by oxidation in basic medium, analogously to the method described in Chem. Ber. 100, 555 (1967); see scheme 8:

25


Scheme 8



5 Compounds of formula (I) in which $n = 0$, X and Y are both N, may be obtained from hydroxyimino derivatives (XV) and R_4 - R_5 -substituted chloroimides of formula (XVI) in basic media, and subsequent treatment of the intermediates with H^+ in refluxing toluene (*J. Org. Chem.*, 58, 7092, (1993)) as described in scheme 9:


10

Scheme 9



15 The compounds of formula (I) in which n is zero, Y is an heteroatom and X is a R_4 - or R_5 -substituted carbon atom (or in which n is 1, X and Y are both nitrogen atoms and the substituents R_5 and R_4 are reversed) can be obtained according to analogous schemes to those shown above, starting from isomer ketones of formula (IIa)

20



(IIa)

which can in their turn be obtained according to the method described in *J. Med.*

Chem. 35, 48 (1992).

The processes of the invention also comprise the conversions of substituent groups into other substituent groups, carried out according to *per se* known methods, on the final compounds (I): for example demethylation of methoxy groups to hydroxy groups, or alkylation of the latter or of SH or NH groups, and the like.

As mentioned before, the compounds of formula (I) exist in more than one stereoisomeric form and the process of the invention produces mixtures thereof.

The individual isomers may be obtained from the enantiomerically pure intermediates.

The individual forms of the compounds of formula (I) may be separated one from another by resolution using an optically active acid such as tartaric acid or O,O'-di-p-toluoyletartaric acid. Alternatively, the single enantiomers can be prepared by an asymmetric synthesis.

The compounds of formula (I) may be converted into their pharmaceutically acceptable acid addition salts by reaction with the appropriate organic or mineral acids.

Solvates of the compounds of formula (I) may be formed by crystallisation or recrystallisation from the appropriate solvent. For example hydrates may be formed by crystallisation or recrystallisation from aqueous solutions or solutions in organic solvents containing water.

The salts or the solvates of the compounds of formula (I) which are not pharmaceutically acceptable can also be useful as intermediates in the preparation of pharmaceutically acceptable salts or solvates. Therefore, said salts or solvates are also part of this invention.

The activity of compounds of formula (I) in standard tests shows they are of potential therapeutic utility in the treatment of pain, in the prevention of rejection in organ transplants and skin grafts and, generally, for the treatment of pathological conditions which can be treated or alleviated by opioid δ receptor agonists or antagonists.

Accordingly the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as an active therapeutic substance.

The present invention further provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

The present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of pain, for the prevention of the rejection of organ transplants and skin grafts and, generally, for the treatment of pathological conditions

which can be treated or alleviated by opioid δ receptor agonists or antagonists. Such a medicament, and a composition of this invention, may be prepared by admixture of a compound of the invention with an appropriate carrier. It may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.

These conventional excipients may be employed for example as in the preparation of compositions of known analgesic agents.

Preferably, a pharmaceutical composition of the invention is in unit dosage form and in a form suitable for use in the medical or veterinarian fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of pain, as an immunomodulating and/or immunosuppressive agent and, generally, as opioid δ receptor agonists or antagonists agents.

The suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient. It will also depend, *inter alia*, upon the relation of potency to adsorbability and the frequency and route of administration.

The compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release of the active ingredient.

Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.

The compositions, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.

Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. When the composition is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk.

Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.

5 Liquid compositions for oral administration may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, 10 carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or 15 propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

The compounds of this invention may also be administered by non-oral route. In accordance with routine pharmaceutical procedure, the compositions may be formulated, for example for rectal administration as a suppository. They may also be 20 formulated, for presentation in an injectable form, in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids. The liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to make the solution isotonic with the blood, thickening agents, suspending 25 agents or other pharmaceutically acceptable additives. Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn, or a solid form or concentrate which can be used to prepare an injectable formulation.

As mentioned earlier, the effective dose of compound depends on the 30 particular compound employed, the condition of the patient and on the frequency and route of administration. A unit dose will generally contain from 20 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg. The composition may be administered once or more times a day, for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will 35 normally be in the range 100 to 3000 mg. Alternatively the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiple doses, if desired, to give the above mentioned daily dose.

No unacceptable toxicological effects are expected with compounds of the invention when administered in accordance with the invention.

The present invention also provides a method for the treatment and/or prophylaxis of pain and of rejection of transplants and skin grafts in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

5 Compounds of this invention and their preparation are illustrated in the following Examples, the preparation of intermediates being illustrated in the Preparations.

PREPARATION 1

N,N-Diethyl-3-oxobutyramide

40 g (0.31 mol) of ethyl acetoacetate and 24 g (0.33 mol) of diethylamine were
 5 stirred in a Parr apparatus at 150 °C for 10'. The crude mixture was distilled at 115-120°C / 9 mmHg, to give 32 g of the title compound.



IR (neat): 2980, 1725, 1640, 1590 cm^{-1} .

N.M.R. 80 MHz (CDCl_3): δ 3.6-3.1 (m, 6H); 2.2 (s, 3H), 1.1 (dt, 6H).

10

PREPARATION 2

N,N-Diethyl-2-phenylhydrazono-3-oxobutyramide

15.7 g (0.1 mol) of N,N-diethyl-3-oxobutyramide were mixed with 12 g (0.14 mol) of CH_3COONa , 20 ml of water and 75 ml of ethanol. The solution obtained was cooled to 10 °C and 0.1 mol of freshly prepared solution of phenyldiazonium chloride [Organic Reactions, R. Adams Ed; Wiley, New York, 10, 32-33, (1951-1959)] were added dropwise. The precipitated solid was filtered, dried *in vacuo* yielding 22.6 g of the title compound. M.p. = 63-65 °C.

20 $\text{C}_{14}\text{H}_{19}\text{N}_3\text{O}_2$

IR (neat): 2970, 1720, 1620, 1605, 1560, 1245 cm^{-1} .

N.M.R. 300 MHz (CDCl_3): δ 9.3 (s, 1H); 7.4-7.2 (m, 5H); 3.6 (q, 2H); 3.2 (q, 2H); 2.5 (s, 3H); 1.35 (t, 3H); 1.2 (t, 3H).

MS (TSP) m/z = 262.1 (MH^+)

25

PREPARATION 3

N,N-Dipropyl-3-oxobutyramide

43.4 g (43.3 mol) of ethyl acetoacetate and 33.7 g (43.3 mol) of dipropylamine were
 30 treated as described in preparation 1. The crude oil was distilled at 86-89 °C / 0.8 mmHg, to give 44.3 g of the title compound.



I.R. (neat): 2980, 1725, 1640, 1590 cm^{-1} .

N.M.R. 80 MHz (CDCl_3): δ 3.45 (s, 2H), 3.4-2.9 (m, 4H), 2.3 (s, 3H), 1.7-1.2 (m, 4H), 0.9-0.6 (t, 6H).


MS (TSP) m/z = 186.3 (MH^+)

PREPARATION 4

N,N-Dipropyl-2-phenylhydrazone-3-oxobutyramide

18.5 g (0.1 mol) of N,N-dipropyl-3-oxobutyramide, 12 g (0.146 mol) of

5 CH_3COONa , 20 ml of water, 75 ml of ethanol and a solution of 0.1 mol of phenyldiazonium chloride were treated as described in preparation 2. The precipitated solid was filtered and dried *in vacuo* yielding 4.2 g of the title compound. M.p. = 79-80 °C.



10 I.R. (KBr): 2970, 1670, 1610, 1495 cm^{-1}

N.M.R. 300 MHz (CDCl_3): δ 7.3 (s, 1H), 7.4-7.0 (m, 5H), 3.5-3.1 (st, 4H), 2.5 (s, 3H), 1.75-1.5 (m, 4H), 1.0 (t, 3H), 0.75 (t, 3H).


MS (TSP) m/z = 290.4 (MH^+)

15 PREPARATION 5

i-Butyl acetoacetate

30 ml of ethyl acetoacetate were dissolved in 350 ml of *i*-butyl alcohol and a catalytic amount of *p*-toluensulphonic acid (PTSA) was added. The solution was refluxed for

20 18 h. The reaction mixture was evaporated *in vacuo* and the residue was dissolved in ether. The resulted solution was treated with s.s. NaHCO_3 . The organic layer was separated, dried over Na_2SO_4 and evaporated *in vacuo*. The crude oil was distilled at 66-68 °C / 4 mmHg, to give 18.8 g of the title compound.




25 MS (TSP) m/z = 159.3 (MH^+)

PREPARATION 6

i-Butyl 2-phenylhydrazone-3-oxobutyrate

30 15.8 g (0.1 mol) of *i*-butyl acetoacetate, 12 g (0.146 mol) of CH_3COONa , 20 ml of water, 75 ml of ethanol and a solution of 0.1 mol of phenyldiazonium chloride were treated as described in preparation 2. The precipitated solid was filtered and dried *in vacuo* yielding 23.1 g of the title compound. M.p. = 45-50 °C.



35 I.R. (KBr): 2970, 1690, 1600, 1530 cm^{-1} N.M.R. 300 MHz (CDCl_3): δ 10-9.2 (bs, 1H), 7.4-7.1 (m, 5H), 4.1 (d, 4H), 2.5 (s, 3H), 1.75-1.5 (m, 4H), 1.0 (t, 3H), 0.75 (t, 3H).

MS (TSP) m/z = 263.3 (MH^+)

PREPARATION 7

N-Benzyl-3-oxobutyramide

9 ml (0.05 mol) of 2,2,6-trimethyl-4H-1,3-dioxin-4-one (diketene-acetone adduct)

5 were added dropwise to a solution of 5.5 ml (0.05 mol) of benzylamine in 20 ml of toluene and the temperature was allowed to rise 70 °C. The solution was refluxed for 2 h then the solvent was removed *in vacuo*. The crude product was triturated with ether obtaining 7.5 g of the title compound. M.p. = 84-86 °C.




10 I.R. (KBr): 3250, 3080, 1720, 1645 cm^{-1}

PREPARATION 8

N-Benzyl-2-phenylhydrazone-3-oxobutyramide

15 7.27 g (0.038) of N-benzyl-3-oxobutyramide were dissolved in a solution of 5.32 g (0.133 mol) of NaOH in 58 ml of water. To the ice-cooled stirred solution, 0.040 mol of phenyldiazonium chloride were added dropwise at such a rate as to keep the temperature at 0 °C. The precipitated solid was filtered and recrystallised from MeOH yielding 9 g of the title compound. M.p. = 101-103 °C.



20 I.R. (KBr): 3300, 1650, 1510, 1245 cm^{-1}

PREPARATION 9

1-(3-Oxobutyl)pyrrolidine

25

9 ml (0.05 mol) of diketene-acetone adduct and a solution of 4.2 ml (0.05 mol) of pyrrolidine in 20 ml of toluene were treated as described in preparation 7. The solvent was removed *in vacuo* and the residue was purified by chromatography on silica gel (EtOAc/MeOH 0% → 1%) yielding 7.6 g of the title compound as a dark oil.



30 I.R. (neat): 2980, 2880, 1725, 1645 cm^{-1}

MS (TSP) m/z = 156 (MH⁺)

PREPARATION 10

1-(2-Phenylhydrazone-3-oxobutyl)pyrrolidine

7.6 g (0.049 mol) of 1-(3-oxobutyl)pyrrolidine, a solution of 6.86 g (0.17 mol) of NaOH in 75 ml of water and 0.051 mol of phenyldiazonium chloride were treated as described in preparation 8. The crude reaction mixture was purified by

chromatography on silica gel (Et₂O) obtaining 8 g of the title compound which was used as such in the subsequent step.

PREPARATION 11

5 N-Phenyl-2-phenylhydrazone-3-oxobutyramide

4.5 g (25.4 mmol) of acetoacetanilide, a solution of 3.46 g (89 mmol) of NaOH in 45 ml of water and 95 mmol of phenyldiazonium chloride were treated as described in preparation 8. The residue was crystallised from EtOH, yielding 3.4 g of the title

10 compound. M.p. = 96-97 °C.



I.R. (KBr): 3080, 1675, 1600, 1520 cm⁻¹


MS (TSP) m/z = 282.2 (MH⁺)

15 PREPARATION 12

N,N-Dimethyl-3-oxobutyramide

A solution of 9 ml (0.05 mmol) of diketene-acetone adduct in 20 ml of toluene was treated with gaseous dimethylamine at room temperature until the reaction was

20 complete. The solvent was removed *in vacuo* and the residue was purified by chromatography on silica gel (EtOAc/MeOH 0%→10%) yielding 7.0 g of the title compound.




I.R. (neat): 2940, 1720, 1640 cm⁻¹

25

PREPARATION 13

N,N-Dimethyl-2-phenylhydrazone-3-oxobutyramide

4.5 g (0.035 mol) of N,N-dimethyl-3-oxobutyramide, a solution of 4.9 g (0.122 mol) 30 of NaOH in 45 ml of water and 0.037 mol of phenyldiazonium chloride were treated as described in preparation 8. The crude reaction mixture was purified by chromatography on silica gel (hexane/Et₂O 0%→100%) obtaining 3.5 g of the title compound which was used as such in the subsequent step. M.p. = 131-133 °C.




35 I.R. (KBr): 3205, 1720, 1630, 1565 cm⁻¹

PREPARATION 14

3-Oxobutyramide

A solution of 9 ml (0.05 mmol) of diketene-acetone adduct in 20 ml of toluene was

5 treated with gaseous ammonia as described in preparation 12. The solvent was removed *in vacuo* and the residue was purified by chromatography on silica gel (EtOAc) yielding 5.0 g of the title compound.




I.R. (neat): 3300, 1730, 1640 cm^{-1}

10

PREPARATION 15

2-Phenylhydrazone-3-oxobutyramide

5.0 g (0.049 mol) of 3-oxobutyramide, a solution of 6.9 g (0.171 mol) of NaOH in 75 ml of water and 0.051 mol of phenyldiazonium chloride were treated as described in preparation 8. The crude reaction mixture was purified by chromatography on silica gel (EtOAc) obtaining 3 g of the title compound which was used as such in the subsequent step. M.p. = 146-147 °C.



15 I.R. (KBr): 3320, 1720, 1520 cm^{-1}

PREPARATION 16

N,N-Diisopropyl-3-oxobutyramide

25 9 ml (0.05 mol) of diketene-acetone adduct and a solution of 47.0 ml (0.05 mol) of diisopropylamine in 20 ml of toluene were treated as described in preparation 7. The solvent was removed *in vacuo* and the residue was purified by chromatography on silica gel (Et₂O) yielding 7.0 g of the title compound as a dark oil.




30 I.R. (neat): 2980, 1725, 1640 cm^{-1}

PREPARATION 17

N,N-Diisopropyl-2-phenylhydrazone-3-oxobutyramide

35 7.0 g (0.038 mol) of N,N-diisopropyl-3-oxobutyramide, a solution of 5.3 g (0.133 mol) of NaOH in 58 ml of water and 0.04 mol of phenyldiazonium chloride were treated as described in preparation 8. The crude reaction mixture was purified by chromatography on silica gel (hexane/Et₂O 95:5) obtaining 7.5 g of the title compound which was used as such in the subsequent step. M.p. = 143-145 °C.



I.R. (KBr): 3210, 2980, 1650, 1620 cm^{-1}

PREPARATION 18

5 Ethyl 2-phenylhydrazone-4,4,4-trifluoro-3-oxobutyrate

7.3 ml (0.05 mol) of ethyl 3-oxo-4,4,4-trifluoroacetoacetate, 6 g (0.073 mol) of CH₃COONa, 20 ml of water, 37.5 ml of ethanol and a solution of 0.05 mol of phenyldiazonium chloride were treated as described in preparation 2. The crude 10 product was purified by chromatography on silica gel (hexane/Et₂O 0%→25%) obtaining 8.65 g of the title compound. M.p. = 78-80 °C.



I.R. (KBr): 1710, 1530 cm^{-1}

15 N.M.R. 300 MHz (DMSO-d₆): δ 12.8 (s, 1H), 7.8-7.2 (m, 5H), 4.2 (q, 2H), 1.5 (t, 3H). MS (EI) m/z = 288.0 (M⁺).

PREPARATION 19

(±)-trans-4a-(3-Methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride

20

A solution of 1.2 g (4.2 mmol) of (±)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline and 1.8 g (12.6 mmol) of proton sponge in 34 ml of 1,2-dichloroethane was treated with 1.4 ml (16.8 mmol) of vinylchloroformate at 0 °C under nitrogen atmosphere. The reaction mixture was 25 stirred at this temperature for 15 min and then refluxed for 3 h, the solvent was removed *in vacuo*, the residue was taken up in water and extracted with Et₂O. The organic layer was washed with 3% HCl, then was dried over Na₂SO₄ and the solvent was removed *in vacuo*. The dark residue was dissolved in EtOH, 3 ml of concentrated HCl were added and the solution refluxed for 3 hours. The solvent was removed *in 30 vacuo*, obtaining 0.88 g of the title compound which was used as such in the subsequent step. M.p. = 90 °C dec..



I.R. (KBr): 3400, 2970, 1715, 1600 cm^{-1}

35 PREPARATION 20

(±)-trans-2-Cyclopropylmethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride

0.88 g (3.08 mmol) of (±)-trans-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-

decahydroisoquinoline hydrochloride, 0.44 g (3.23 mmol) of cyclopropylmethyl bromide, 0.64 g of potassium carbonate and a catalytical amount of potassium iodide in 15.4 ml of DMF were stirred at 60 °C for 2 h. The solvent was removed *in vacuo*, and the crude product was purified by flash chromatography

5 (EtOAc/MeOH/conc.NH₄OH 90:10:0.8). The solid product was dissolved in acetone and the solution brought to acidic pH with HCl/Et₂O. The precipitate was filtered, yielding 0.28 g of the title compound. M.p. = 78 °C dec.



I.R. (KBr): 3400, 2940, 1715, 1600 cm⁻¹

10 N.M.R. 300 MHz (DMSO-d₆): δ 7.4-6.8 (m, 4H), 3.8 (s, 3H), 3.6-1.1 (m, 16H), 0.6 (m, 2H), 0.4 (m, 2H).

MS (EI) m/z = 314.2 (MH⁺).

PREPARATION 21

15 (±)-trans-2-Diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

A solution of 0.6 g (1.42 mmol) of (±)-trans-2-diethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline

20 hydrochloride and 0.6 g (2.48 mmol) of proton sponge in 35 ml of 1,2-dichloroethane was treated with 0.245 ml (2.48 mmol) of vinylchloroformate and then with conc. HCl in EtOH as described in preparation 19, obtaining 0.36 g of the title compound.



I.R. (KBr): 3400, 2970, 1755, 1600 cm⁻¹

25

PREPARATION 22

(±)-trans-2-Butyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline

30 0.71 g (2.55 mmol) of (±)-trans-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 0.37 g (2.68 mmol) of butyl bromide, 0.53 g of potassium carbonate and a catalytical amount of potassium iodide in 15 ml of DMF were reacted as described in preparation 20, yielding 0.2 g of the title compound which was used as such in the subsequent step.

35 C₂₀H₂₉NO₂

I.R. (neat): 3400, 2930, 1715, 1605 cm⁻¹

PREPARATION 23

(\pm)-trans-2-Ethyl-6-hydroxyimino-4a-(3-methoxyphenyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline

5 0.5 g (1.54 mmol) of (\pm)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 0.456 g (6.56 mmol) of hydroxylamine hydrochloride and 0.64 g of KHCO_3 in 10 ml of MeOH were refluxed for 45 min. The precipitate was filtered, the solvent was removed *in vacuo* and the residue taken up in H_2O . The pH was adjusted to 8 with conc. NH_4OH , the aqueous layer was extracted with CH_2Cl_2 . The organic layer was dried, the solvent removed *in vacuo*, obtaining 0.45 g of the title compound which was used as such in the subsequent step.

10 $\text{C}_{18}\text{H}_{26}\text{N}_2\text{O}_2$

I.R. (KBr): 2940, 2820, 1605, 1580 cm^{-1}

15

PREPARATION 24

(\pm)-trans-2-Diisopropylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrido[2,3-g]isoquinoline hydrochloride

20 A solution of 0.57 g (1.26 mmol) of (\pm)-trans-2-diisopropylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrido[2,3-g]isoquinoline and 0.54 g (4.52 mmol) of proton sponge in 35 ml of 1,2-dichloroethane was treated with 0.77 ml (4.52 mmol) of vinyl chloroformate and then with conc. HCl in EtOH as described in preparation 19, obtaining 0.34 g of the title compound.

25 $\text{C}_{26}\text{H}_{37}\text{N}_3\text{O}_2\cdot\text{HCl}$

I.R. (KBr): 3400, 2970, 1755, 1600 cm^{-1}

EXAMPLE 1

(\pm)-trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline

5 1.6 g (4.9 mmol) of (\pm)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride (*J. Med. Chem.*, **54**, 1442, 1989) and 1.54 g (5.8 mmol) of N,N-diethyl-2-phenylhydrazone-3-oxobutyramide were dissolved in a mixture of 5 ml of glacial acetic acid and 0.48 g (5.8 mmol) of CH₃COONa. The solution was heated to 60 °C then, under N₂ atmosphere, 1.47 g (22.5 mmol) of zinc dust were added portionwise. The resulting mixture was refluxed for 2 h and cooled to room temperature. The precipitate was removed by decantation and washed with 5 ml of glacial acetic acid. The combined acidic solutions were diluted with iced water (50 ml), the pH was adjusted to 8 with 20% NaOH and then extracted with AcOEt. The organic layer was dried over Na₂SO₄ and the solvent was removed *in vacuo*. The residue was purified by flash chromatography (AcOEt/MeOH/conc. NH₄OH 90:10:1; R_f = 0.25), yielding 1.4 g of the title compound. M.p. (HCl salt) = 247 °C dec.

10 C₂₆H₃₇N₃O₂
I.R. (KBr) (-HCl): 3410, 3200, 2920, 2500, 1600, 1580 cm⁻¹.

15 N.M.R. 80 MHz (CDCl₃): δ 7.3 (s, 1H), 7.2-6.6 (m, 4H), 3.7 (s, 3H), 3.6-2.0 (m, 20H), 1.95 (s, 3H), 1.2-0.9 (m, 6H).

20 MS (TSP) m/z = 424.2 (MH⁺)

EXAMPLE 2

25 (\pm)-trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

To a solution of 1.89 ml (20.2 mmol) of boron tribromide in 40 ml of dry CHCl₃, 1.43 g (3.37 mmol) of (\pm)-trans-2-diethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3g] isoquinoline dissolved in 15 ml of dry CHCl₃ were added, under N₂ atmosphere, at room temperature. After 2 h the mixture was poured in 200 g of ice containing 20 ml of conc. NH₄OH. The organic layer was separated, dried over Na₂SO₄ and the solvent removed *in vacuo*. The residue was purified by flash chromatography (AcOEt/MeOH/conc. NH₄OH 80:20:2), obtaining 0.8 g of the title compound. M.p. = 221-223 °C

C₂₅H₃₅N₃O₂

I.R. (KBr): 3500, 2940, 1575, 1300 cm⁻¹.

N.M.R. 300 MHz (DMSO-d6): δ 10.25 (s, 1H), 8.55 (s, 1H), 7.0-6.8 (m, 3H), 6.45

(d, 1H), 2.85-1.85 (m, 20H), 1.95 (s, 3H), 1.0 (dt, 6H).

MS (TSP) m/z = 410.2 (MH⁺)

EXAMPLE 3

5 (±)-trans-6-Ethyl-2-ethoxycarbonyl-3-methyl-8a-(3-methoxyphenyl)-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

10 0.8 g (2.47 mmol) of (±)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-
1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride and 0.87 g (93.7 mmol) of
ethyl 2-phenylhydrazone-3-oxobutyrate [Organic Reactions, R. Adams Ed; Wiley,
New York, 10, 32-33, (1951-1959)] were dissolved in a mixture of 3 ml of glacial
acetic acid and 0.34 g (4.2 mmol) of CH₃COONa. The solution was treated as
described in example 1 adding 0.74 g (11.3 mmol) of zinc dust. The residue was
purified by flash chromatography (AcOEt/MeOH/conc. NH₄OH 94:5:0.5; R_f = 0.3),
15 obtaining 0.6 g of the title compound.

C₂₄H₃₂N₂O₃

I.R. (KBr): 3300, 2915, 1680, 1600, 1445 cm⁻¹

N.M.R. 300 MHz (DMSO-d₆): δ 10.8 (s, 1H), 7.2-6.6 (m, 4H), 4.1 (q, 2H), 3.65 (s,
3H), 3.1-2.2 (m, 11H), 2.1 (s, 3H), 1.7 (d, 2H), 1.1(t, 3H), 0.95 (t, 3H).

20 MS (TSP) m/z = 397.2 (MH⁺)

EXAMPLE 4

(±)-trans-6-Ethyl-2-ethoxycarbonyl-8a-(3-hydroxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

25 0.6 g (1.5 mmol) of (±)-trans-6-ethyl-2-ethoxycarbonyl-3-methyl-8a-(3-
methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline were
treated with 0.84 ml (9.0 mmol) of boron tribromide as described in example 2. The
crude solid was purified by flash chromatography (AcOEt/MeOH/conc. NH₄OH
30 80:20:2), yielding 0.12 g of the title compound. M.p. = 195 -197 °C

C₂₃H₃₀N₂O₃

I.R. (KBr): 3300, 2920, 1690, 1440 cm⁻¹.

N.M.R. 300 MHz (DMSO-d₆): δ 10.8 (s, 1H), 9.1 (s, 1H), 7.1-6.4 (m, 3H), 4.1 (q,
2H), 3.45-1.75 (m, 14H), 2.1 (s, 3H), 1.2 (t, 3H), 1.0 (t, 3H).

35 MS (TSP) m/z = 383.1 (MH⁺)

EXAMPLE 5

(\pm)-trans-Dipropylaminocarbonyl-6-ethyl-3-methyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

5 0.7 g (2.16 mmol) of (\pm)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 0.62 g (2.16 mmol) of N,N-dipropyl-2-phenylhydrazone-3-oxobutyramide, 0.21 g (2.6 mmol) of CH₃COONa, 0.65 g (10 mmol) of zinc dust and 2.5 ml of glacial acetic acid were treated as described in example 1. The residue was purified by flash chromatography (AcOEt/MeOH/conc. NH₄OH 90:10:1.5; R_f = 0.3), dissolved in Et₂O and the solution brought to acidic pH with HCl/Et₂O. The precipitate was filtered and recrystallised from a mixture of AcOEt/Acetone = 9/1, yielding 0.65 g of the title compound.

M.p. = 250 °C dec.

15 C₂₈H₄₁N₃O₂ · HCl

I.R. (KBr): 3400, 3210, 2970, 1600, 1580 cm⁻¹

N.M.R. 300 MHz (CDCl₃): δ 12 (bs, 1H), 8.5 (s, 1H), 7.4-6.6 (m, 4H), 3.8-2.5 (m, 17H), 2.0 (s, 3H), 1.8-1.3 (m, 10H), 0.9 (t, 6H).

MS (TSP) m/z (free base) = 452.7 (MH⁺)

20

EXAMPLE 6

(\pm)-trans-Dipropylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

25 0.56 g (1.15 mmol) of (\pm)-trans-dipropylaminocarbonyl-6-ethyl-3-methyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride were treated with 0.65 ml (7 mmol) of boron tribromide as described in example 2. The residue was purified by flash chromatography (AcOEt/MeOH/conc. NH₄OH 75:25:2.5). The crude product was crystallised from acetone yielding 0.075 g of the title compound. M.p. = 151-153 °C.

C₂₇H₃₉N₃O₂

I.R. (KBr): 3150, 2970, 1590, 1450 cm⁻¹

N.M.R. 300 MHz (DMSO-d₆): δ 10.2 (s, 1H), 9.1 (s, 1H), 7.2-6.4 (m, 4H), 3.5-1.8 (m, 17H), 1.9 (s, 3H), 1.6-1.4 (m, 4H), 1.0 (t, 3H), 0.8 (t, 6H).

35 MS (TSP) m/z = 438.4 (MH⁺)

EXAMPLE 7

(\pm)-trans-2-(*i*-Butoxycarbonyl)-6-ethyl-3-methyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

5 0.7 g (2.16 mmol) of (\pm)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 0.56 g (2.16 mmol) of *i*-butyl 2-phenylhydrazono-3-oxobutyrate, 0.21 g (2.6 mmol) of CH₃COONa, 0.65 g (10 mmol) of zinc dust and 2.5 ml of glacial acetic acid were treated as described in example 1. The residue was purified by flash chromatography (AcOEt/MeOH/conc. 10 NH₄OH 90:10:1.5; R_f = 0.27). The purified free base was dissolved in AcOEt and the solution brought to acidic pH with HCl/Et₂O. The precipitate was filtered, washed and dried, to yield 0.56 g of the title compound. M.p. = 230 °C dec.

C₂₆H₃₆N₂O₃·HCl
I.R. (KBr): 3400, 2970, 1670, 1600 cm⁻¹
15 N.M.R. 300 MHz (CDCl₃): δ 9.7 (bs, 1H), 8.4 (s, 1H), 7.3-6.6 (m, 4H), 4.0 (d, 2H), 3.8 (s, 3H), 3.6-2.5 (m, 13H), 2.2 (s, 3H), 2.1-1.4 (m, 4H), 1.0 (d, 6H).

EXAMPLE 8

(\pm)-trans-2-(*i*-Butoxycarbonyl)-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

0.56 g of (\pm)-trans-2-(*i*-butoxycarbonyl)-6-ethyl-3-methyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride were treated with 0.68 ml (7.26 mmol) of boron tribromide as described in example 2. The 25 residue was purified by flash chromatography (AcOEt/MeOH/conc. NH₄OH 75:25:2.5) and then crystallised from AcOEt yielding 0.1 g of the title compound. M.p. = 196-198 °C

C₂₅H₃₄N₂O₃


I.R. (KBr): 2960, 1620, 1580, 1320 cm⁻¹
30 N.M.R. 300 MHz (DMSO-d₆): δ 9.2 (s, 1H), 8.5 (s, 1H), 7.0-6.2 (m, 4H), 3.8 (d, 2H), 3.0-1.8 (m, 14H), 2.1 (s, 3H), 1.1-0.9 (m, 9H).
MS (TSP) m/z = 411.4 (MH⁺)

EXAMPLE 9

35 (\pm)-trans-2-Diethylaminocarbonyl-3,6-dimethyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

3 g (9.3 mmol) of (\pm)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 2.92 g (11.2 mmol) of

N,N-diethyl-2-phenylhydrazone-3-oxobutyramide, 0.92 g (11.2 mmol) of CH₃COONa, 2.8 g (42.8 mmol) of zinc dust and 9.3 ml of glacial acetic acid were treated as described in example 1. The residue was purified by flash chromatography (AcOEt/MeOH/conc. NH₄OH 90:10:1; R_f = 0.27) yielding 0.56 g of the title compound. M.p. (·HCl) = 250 °C dec.




I.R. (KBr) (hydrochloride): 3410, 3200, 2915, 2510, 1605, 1580 cm⁻¹.

EXAMPLE 10

10 (±)-trans-2-Diethylaminocarbonyl-3,6-dimethyl-8a-(3-hydroxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

15 0.5 g (1.22 mmol) of (±)-trans-2-diethylaminocarbonyl-3,6-dimethyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline were treated with 0.68 ml (7.26 mmol) of boron tribromide as described in example 2. The residue was purified by flash chromatography (AcOEt/MeOH/conc. NH₄OH 75:25:2.5). The crude product was dissolved in MeOH and the solution brought to acidic pH with HCl/Et₂O. The solvent was evaporated *in vacuo* and the solid crystallised from a mixture of acetone/MeOH = 1:1, yielding 0.06 g of the title

20 compound. M.p. = >250 °C



I.R. (KBr): 3450, 3120, 2970, 1600, 1580 cm⁻¹


N.M.R. 300 MHz (DMSO-d₆): δ 10.4 (s, 1H), 9.2 (s, 1H), 7.2-6.5 (m, 4H), 3.5-2.0 (m, 15H), 2.8 (s, 3H), 1.9 (s, 3H), 1.0 (t, 6H).

25 MS (TSP) m/z(free base) = 396.4 (MH⁺)

EXAMPLE 11

(±)-trans-2-Diethylaminocarbonyl-3,7-dimethyl-4a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[3,2-g]isoquinoline

30 0.9 g (2.9 mmol) of (±)-trans-2-ethyl-4a-(3-methoxyphenyl)-7-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride (*J. Med. Chem.*, 35, 48, 1992), 0.9 g (3.5 mmol) of N,N-diethyl-2-phenylhydrazone-3-oxobutyramide, 0.28 g (3.5 mmol) of CH₃COONa, 0.87 g (13.3 mmol) of zinc dust and 5 ml of glacial acetic acid were treated as described in example 1. The residue was purified by flash chromatography (CH₂Cl₂/MeOH/conc. NH₄OH 86:10:0.6; R_f = 0.27), to yield 0.2 g of the title compound. M.p. = 153-155 °C dec.



I.R. (KBr): 3250, 2920, 1605, 1580 cm⁻¹.

N.M.R. 300 MHz (CDCl_3): δ 8.2 (s, 1H), 7.1-6.6 (m, 4H), 3.7 (s, 3H), 3.6-1.95 (m, 15H), 2.3 (s, 3H), 1.9 (s, 3H), 1.1 (t, 6H).
 MS (TSP) m/z = 410.5 (MH^+)

5

EXAMPLE 12

(\pm)-trans-2-Diethylaminocarbonyl-3,7-dimethyl-4a-(3-hydroxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[3,2-g]isoquinoline

10 0.29 g (0.71 mmol) of (\pm)-trans-2-diethylaminocarbonyl-3,7-dimethyl-4a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[3,2-g] isoquinoline were treated with 0.4 ml (4.26 mmol) of boron tribromide as described in example 2. The residue was purified by flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{conc. NH}_4\text{OH}$ 80:12:0.8). The crude product was triturated with a mixture of acetone/MeOH = 3:2, 15 yielding 0.14 g of the title compound. M.p. = 235-238 °C

$\text{C}_{24}\text{H}_{33}\text{N}_3\text{O}_2$

I.R. (KBr): 3215, 2920, 1610, 1510 cm^{-1}

N.M.R. 300 MHz (DMSO-d_6): δ 10.4 (s, 1H), 9.1 (s, 1H), 7.0-6.4 (m, 4H), 3.4-2.0 (m, 15H), 2.2 (s, 3H), 1.9 (s, 3H), 1.0 (t, 6H).

20 MS (TSP) m/z = 396.4 (MH^+)

EXAMPLE 13

(\pm)-trans-2-Benzylaminocarbonyl-3,6-dimethyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

25 1 g (3.3 mmol) of (\pm)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 2.95 g (10 mmol) of N-benzyl-2-phenylhydrazone-3-oxobutyramide, 0.82 g (10 mmol) of CH_3COONa , 2.6 g (40 mmol) of zinc dust and 5 ml of glacial acetic acid were treated as described in 30 example 1. The residue was crystallised from AcOEt yielding 0.65 g of the title compound. M.p. = 162-164 °C.

$\text{C}_{28}\text{H}_{33}\text{N}_3\text{O}_2$

I.R. (KBr): 3350, 3220, 2920, 1640, 1630, 1510 cm^{-1} .

35 EXAMPLE 14

(\pm)-trans-2-Benzylaminocarbonyl-3,6-dimethyl-8a-(3-hydroxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

0.38 g of (\pm)-trans-2-benzylaminocarbonyl-3,6-dimethyl-8a-(3-methoxyphenyl)-

4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline were treated with 0.55 ml (5.7 mmol) of boron tribromide as described in example 2. The residue was dissolved in MeOH and the solution brought to acidic pH with HCl/Et₂O. The solvent was evaporated *in vacuo* and the solid crystallised from a mixture of acetone/MeOH = 1:1, 5 yielding 0.15 g of the title compound. M.p. = 297-299 °C

C₂₇H₃₁N₃O₂·HCl

I.R. (KBr): 3290, 2910, 1650, 1540, 1320 cm⁻¹

EXAMPLE 15

10 (±)-trans-3,6-Dimethyl-8a-(3-methoxyphenyl)-2-pyrrolidinocarbonyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

15 1 g (3.3 mmol) of (±)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-
1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 2.6 g (10 mmol) of 1-(2-phenylhydrazono-3-oxobutyl)pyrrolidine, 0.82 g (10 mmol) of CH₃COONa, 2.6 g (40 mmol) of zinc dust and 5 ml of glacial acetic acid were treated as described in example 1. The residue was purified by chromatography on silica gel (EtOAc/MeOH 0%→5%) then crystallised from a mixture of acetone/MeOH = 1:1 yielding 0.65 g of the title compound. M.p. = 171-173 °C.

20 C₂₅H₃₃N₃O₂

I.R. (KBr): 3280, 2940, 1610, 1580 cm⁻¹.

EXAMPLE 16

25 (±)-trans-3,6-Dimethyl-8a-(3-hydroxyphenyl)-2-pyrrolidinocarbonyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

30 0.38 g of (±)-trans-3,6-dimethyl-8a-(3-methoxyphenyl)-2-pyrrolidinocarbonyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline were treated with 0.55 ml (5.7 mmol) of boron tribromide as described in example 2. The residue was triturated in Et₂O and the solution brought to acidic pH with HCl/Et₂O. The solvent was evaporated *in vacuo* and the solid crystallised from a mixture of acetone/MeOH = 1:1, yielding 0.15 g of the title compound. M.p. = 230-233 °C

C₂₄H₃₁N₃O₂·HCl

I.R. (KBr): 3400, 3140, 1600, 1580, 1510 cm⁻¹

35


EXAMPLE 17

(±)-trans-6-Ethyl-3-methyl-8a-(3-methoxyphenyl)-2-phenylaminocarbonyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

0.8 g (2.47 mmol) of (±)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-

1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 0.7 g (2.47 mmol) of N-phenyl-2-phenylhydrazone-3-oxobutyramide, 0.24 g (3 mmol) of CH₃COONa, 0.74 g (11.3 mmol) of zinc dust and 2.5 ml of glacial acetic acid were treated as described in example 1. The residue was purified by flash chromatography

5 (EtOAc/MeOH/conc. NH₄OH 90:10:1) yielding 0.28 g of the title compound. M.p. = 178-180 °C.



I.R. (KBr): 3280, 2940, 1640, 1590 cm⁻¹.

10 N.M.R. 300 MHz (CDCl₃): δ 7.6-6.6 (m, 9H), 3.75 (s, 3H), 3.0-2.4 (m, 14H), 1.9 (q, 2H), 1.1 (t, 3H).

MS (TSP) m/z = 444.5 (MH⁺)

EXAMPLE 18

(±)-trans-6-Ethyl-8a-(3-hydroxyphenyl)-3-methyl-2-phenylaminocarbonyl-

15 4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

0.28 g of (±)-trans-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-2-phenylaminocarbonyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline were treated with 0.35 ml (1.9 mmol) of boron tribromide as described in example 2. The residue was purified 20 by flash chromatography (EtOAc/MeOH/conc. NH₄OH 80:20:2) yielding 0.06 g of the title compound. M.p. = 271-272 °C.



I.R. (KBr): 3310, 294, 1640, 1590 cm⁻¹

25 N.M.R. 300 MHz (DMSO-d₆): δ 10.6 (s, 1H), 9.2 (ds, 2H), 7.5-6.4 (m, 9H), 3.0-1.9 (m, 13H), 2.2 (s, 3H), 1.0 (t, 3H).

MS (TSP) m/z = 430.5 (MH⁺)

EXAMPLE 19

(±)-trans-2-Diethylaminothiocarbonyl-6-ethyl-3-methyl-8a-(3-methoxyphenyl)-

30 4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

1 g (2.4 mmol) of (±)-trans-2-diethylaminocarbonyl-6-ethyl-3-methyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline prepared as described in example 1 and 0.48 g (1.2 mmol) of Lawesson reagent (*Synthesis*, 35 941, 1979) were dissolved in 50 ml of toluene. The solution was refluxed for 6 h. The solvent was evaporated *in vacuo*. The residue was treated with s.s. K₂CO₃ and extracted with AcOEt. The organic layers were dried over Na₂SO₄ and then the solvent evaporated *in vacuo*. The crude product was purified by flash chromatography (AcOEt/MeOH/conc. NH₄OH 80:20:2) yielding 0.5 g of the title compound. M.p. =

156-158 °C.

$C_{26}H_{37}N_3OS$

I.R. (nujol): 1600, 1581, 1461, 1378 cm^{-1} .

N.M.R. 300 MHz (CDCl_3): δ 8.3 (s, 1H), 7.2-6.7 (m, 4H), 4.0-3.8 (m, 4H), 3.75 (s,

5 3H), 3.0-1.9 (m, 13H), 1.9 (s, 3H), 1.2 (t, 6H), 1.1(t, 3H).

MS (TSP) m/z = 440.6 (MH^+)

EXAMPLE 20

(\pm)-trans-2-Diethylaminothiocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-

10 4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

0.5 g of (\pm)-trans-2-diethylaminothiocarbonyl-6-ethyl-3-methyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline were treated with 0.64 ml (6.8 mmol) of boron tribromide as described in example 2. The residue was purified by flash chromatography ($\text{EtOAc}/\text{MeOH}/\text{conc. NH}_4\text{OH}$ 80:20:2) yielding 0.12 g of the title compound. M.p = 243-245 °C.

$C_{25}H_{35}N_3OS$

I.R. (KBr): 3200, 2900, 1580, 1480 cm^{-1}

N.M.R. 300 MHz (DMSO-d_6): δ 10.2 (s, 1H), 9.2 (s, 1H), 7.1-6.4 (m, 4H), 3.9-3.7

20 (m, 6H), 3.0-1.75 (m, H), 1.8 (s, 3H), 1.1 (t, 6H), 0.9 (t, 3H).

MS (TSP) m/z = 426.3 (MH^+)

EXAMPLE 21

(\pm)-trans-6-Cyclopropylmethyl-2-diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-

25 methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride

0.28 g (0.80 mmol) of (\pm)-trans-2-cyclopropylmethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 0.56 g (2.14 mmol) of N,N-diethyl-2-phenylhydrazone-3-oxobutyramide, 0.131 g (1.6 mmol) of

30 CH_3COONa , 0.402 g (6.16 mmol) of zinc dust and 10 ml of glacial acetic acid were treated as described in example 1. The residue was purified by flash chromatography ((i-Pr)₂O/ $\text{MeOH}/\text{conc. NH}_4\text{OH}$ 90:10:0.5). The product was dissolved in acetone and the solution brought to acidic pH with $\text{Et}_2\text{O}/\text{HCl}$. The solid was filtered, washed and dried yielding 0.225 g of the title compound. M.p. = 190-195 °C.

35 $C_{28}H_{39}N_3O_2 \cdot \text{HCl}$

I.R. (KBr): 3400, 3200, 2915, 2580, 1715, 1600 cm^{-1}

N.M.R. 300 MHz (DMSO-d_6): δ 10.3 (bs, 1H), 10.2 (s, 1H), 7.3-6.7 (m, 4H), 3.7 (s, 3H), 3.6-2.5 (m, 14H), 2.5 (s, 3H), 2.1-1.4 (m, 4H), 1.0 (t, 6H), 0.6 (m, 2H), 0.4 (m, 2H).

MS (EI) m/z = 450.5 (MH⁺)

EXAMPLE 22

(±)-trans-6-Cyclopropylmethyl-2-diethylaminocarbonyl-8a-(3-hydroxyphenyl)-3-

5 methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride

0.225 g (0.46 mmol) of (±)-trans-6-cyclopropylmethyl-2-diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]

isoquinoline were treated with 0.26 ml (2.76 mmol) of boron tribromide as described

10 in example 2. The residue was purified by flash chromatography ((i-Pr)₂O/MeOH/conc. NH₄OH 75:25:0.5). The crude product was dissolved in acetone and the solution brought to acidic pH with HCl/Et₂O. The precipitate was filtered yielding 0.07 g of the title compound. M.p. = 270-272 °C dec.

C₂₇H₃₇N₃O₂·HCl

15 I.R. (KBr): 3010, 2700, 1595, 1580 cm⁻¹

N.M.R. 300 MHz (DMSO-d₆): δ 10.4 (bs, 1H), 10.3 (s, 1H) 9.2 (s, 1H), 7.1-6.5 (m, 4H), 3.5-2.0 (m, 15H), 2.8 (s, 3H), 1.9 (s, 3H), 1.0 (t, 6H), 0.6 (m, 2H), 0.4 (m, 2H).

MS (EI) m/z(free base) = 435.3 (M⁺)

20 **EXAMPLE 23**

(±)-trans-2-Diisopropylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-

4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline

0.7 g (2.2 mmol) of (±)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-

25 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 2.0 g (7.0 mmol) of N,N-diisopropyl-2-phenylhydrazone-3-oxobutyramide, 0.575 g (7.0 mmol) of CH₃COONa, 1.83 g (28.0 mmol) of zinc dust and 3.5 ml of glacial acetic acid were treated as described in example 1 yielding 1.0 g of the title compound as an oil.

C₂₈H₄₁N₃O₂

30 I.R. (neat) : 3250, 2960, 2580, 1740, 1600 cm⁻¹

N.M.R. 300 MHz (DMSO-d₆) (hydrochloride): δ 10.2 (s, 1H), 7.2-6.6 (m, 4H), 3.7 (s, 3H), 3.6-1.8 (m, 18H), 1.8 (s, 3H), 1.0 (d, 12H), .

MS (EI) m/z = 451.3 (M⁺).

35 **EXAMPLE 24**

(±)-trans-2-Diisopropylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-

4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

1.0 g (2.2 mmol) of (±)-trans-2-diisopropylaminocarbonyl-6-ethyl-8a-(3-

methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline were treated with 1.15 ml (12.0 mmol) of boron tribromide as described in example 2. The crude product was dissolved in MeOH and the solution brought to acidic pH with HCl/Et₂O. The solvent was evaporated *in vacuo* and the solid

5 crystallized from acetone, yielding 0.5 g of the title compound. M.p. = 263-265 °C
 $C_{27}H_{39}N_3O_2 \cdot HCl$
 I.R. (KBr): 3110, 2960, 1720, 1595, cm⁻¹
 N.M.R. 300 MHz (DMSO-d₆): δ 10.4 (s, 1H), 10.3 (bs, 1H), 9.2 (s, 1H), 7.1-6.5 (m, 4H), 3.7-2.0 (m, 18H), 1.8 (s, 3H), 1.0 (d, 12H).
 10 MS (EI) m/z = 437.3 (M⁺).

EXAMPLE 25

(\pm)-trans-2-Aminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline


15 3.24 g (10 mmol) of (\pm)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 6.16 g (30.0 mmol) of 2-phenylhydrazone-3-oxobutyramide, 2.46 g (7.0 mmol) of CH₃COONa, 7.85 g (120.0 mmol) of zinc dust and 15 ml of glacial acetic acid were treated as described in

20 example 1. The residue was purified by chromatography on silica gel (Et₂O-EtOAc/MeOH 0% \rightarrow 50%) yielding 3.0 g of oily product which was triturated in Et₂O yielding 2.5 g of the title compound. M.p. = 176-178 °C
 $C_{22}H_{29}N_3O_2$
 I.R. (neat) : 3200, 2915, 2580, 1640, 1600, 1580 cm⁻¹
 25 N.M.R. 300 MHz (DMSO-d₆) : δ 10.4 (s, 1H), 7.2-6.5 (m, 4H), 3.8 (s, 3H), 3.0-1.8 (m, 18H), 1.0 (t, 3H).
 MS (EI) m/z = 368.1 (MH⁺).

EXAMPLE 26

30 (\pm)-trans-2-Aminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride

35 0.48 g (1.3 mmol) of (\pm)-trans-2-aminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline were treated with 0.75 ml (7.8 mmol) of boron tribromide as described in example 2. The crude product was purified by chromatography on silica gel (CH₂Cl₂/MeOH 20% \rightarrow 30%). The residue was dissolved in MeOH and the solution brought to acidic pH with HCl/Et₂O. The solvent was evaporated *in vacuo* and the solid crystallized from acetone/MeOH, yielding 0.13 g of the title compound. M.p. = 270-273 °C



I.R. (KBr): 3160, 1645, 1595, 1450 cm^{-1}

N.M.R. 300 MHz (DMSO-d₆): δ 10.5 (s, 1H), 10.2 (bs, 1H), 7.2-6.5 (m, 4H), 3.7-2.0 (m, 16H), 2.0 (s, 3H), 1.2 (t, 3H).

5 MS (EI) m/z = 354.1 (MH⁺).


EXAMPLE 27

(\pm)-trans-6-Ethyl-2-ethoxycarbonyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-3-trifluoromethyl-1H-pyrido[2,3-g]isoquinoline

10

3.24 g (10 mmol) of (\pm)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 8.65 g (30 mmol) of ethyl 2-phenylhydrazone-4,4,4-trifluoro-3-oxobutyrate, 2.46 g (30 mmol) of CH₃COONa, 7.85 g (120 mmol) of zinc dust and 15 ml of glacial acetic acid were treated as

15 described in example 1. The residue was purified by chromatography on silica gel (EtOAc/MeOH 0% \rightarrow 10%) yielding 3.0 g of product which was triturated in Et₂O yielding 2.5 g of the title compound. M.p. 209-211 °C



I.R. (neat) : 3000, 1725, 1680, 1600 cm^{-1}

20 N.M.R. 300 MHz (DMSO-d₆) (hydrochloride): δ 12.0 (s, 1H), 7.2-6.6 (m, 4H), 4.2 (q, 2H), 3.8 (s, 3H), 3.6-1.8 (m, 13H), 1.2 (t, 3H), 1.0 (t, 3H).

MS (EI) m/z = 451.1 (MH⁺).

EXAMPLE 28

25 (\pm)-trans-6-Ethyl-2-ethoxycarbonyl-8a-(3-hydroxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-3-trifluoromethyl-1H-pyrido[2,3-g]isoquinoline hydrochloride

0.6 g (1.3 mmol) of (\pm)-trans-6-ethyl-2-ethoxycarbonyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-octahydro-3-trifluoromethyl-1H-pyrido[2,3-g]isoquinoline were 30 treated with 0.75 ml (7.8 mmol) of boron tribromide as described in example 2. The crude product was purified by chromatography on silica gel (CH₂Cl₂/MeOH 20% \rightarrow 30%). The residue was dissolved in MeOH and the solution brought to acidic pH with HCl/Et₂O. The solvent was evaporated *in vacuo* and the solid was triturated in Et₂O, yielding 0.14 g of the title compound. M.p. = 275-278 °C

35 C₂₃H₂₇F₃N₂O₃·HCl

I.R. (KBr): 3160, 2680, 1705, 1600, cm^{-1}

N.M.R. 300 MHz (DMSO-d₆): δ 12.1 (s, 1H), 10.4 (bs, 1H), 9.3 (s, 1H), 7.2-6.5 (m, 4H), 4.2 (q, 2H), 3.7-2.2 (m, 10H), 2.0 (s, 3H), 1.2 (m, 6H).

MS (EI) m/z = 436.1 (M⁺).

EXAMPLE 29

(\pm)-trans-2-Diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-6-propyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

5 0.37 g (0.86 mmol) of (\pm)-trans-2-diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride, 0.11 g (0.90 mmol) of propyl bromide, 0.24 g (1.71 mmol) of potassium carbonate and a catalytic amount of potassium iodide were dissolved in 5 ml of
 10 dimethylformamide and heated to 80 °C for 2 h. The solvent was evaporated *in vacuo*, the residue was taken up in H₂O and extracted with EtOAc. The organic layer was separated, dried over Na₂SO₄ and the solvent removed *in vacuo*. The residue was dissolved in Et₂O and the solution brought to acidic pH with HCl/Et₂O. The precipitate was filtered yielding 0.25 g of the title compound. M.p. = 102-106 °C
 15 dec.



I.R. (KBr) : 3400, 3200, 2915, 2580, 1715, 1600 cm⁻¹

EXAMPLE 30

20 (\pm)-trans-2-Diethylaminocarbonyl-8a-(3-hydroxyphenyl)-3-methyl-6-propyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride
 25 0.25 g (0.53 mmol) of (\pm)-trans-2-diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-6-propyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride were treated with 0.3 ml (3.18 mmol) of boron tribromide as described in example 2. The crude product was dissolved in MeOH and the solution brought to acidic pH with HCl/Et₂O. The solvent was evaporated *in vacuo* and the solid crystallized from acetone, yielding 0.04 g of the title compound. M.p. = 236-238 °C.
 C₂₆H₃₇N₃O₂·HCl
 30 I.R. (KBr): 3130, 2915, 1590, 1460, cm⁻¹
 N.M.R. 300 MHz (DMSO-d₆): δ 10.2 (s, 1H), 9.0 (s, 1H), 7.2-6.4 (m, 4H), 3.7-2.2 (m, 12H), 2.0 (s, 3H), 1.8 (m, 2H), 1.6 (m, 2H), 1.0 (t, 6H), 0.8 (t, 6H).
 MS (EI) m/z = 423.2 (M⁺).


35 EXAMPLE 31

(\pm)-trans-2-Dimethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline

1.0 g (3.1 mmol) of (\pm)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-

1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 2.33 g (10 mmol) of N,N-dimethyl-2-phenylhydrazone-3-oxobutyramide, 0.82 g (10 mmol) of CH₃COONa, 2.6 g (40 mmol) of zinc dust and 5 ml of glacial acetic acid were treated as described in example 1. The residue was purified by chromatography on silica gel

5 (EtOAc/MeOH 0%→30%) yielding 0.5 g of product which was crystallized from Et₂O yielding 0.5 g of the title compound. M.p. = 151-153 °C



I.R. (neat) : 3210, 2910, 1585 cm⁻¹

N.M.R. 300 MHz (DMSO-d₆) (hydrochloride): δ 10.3 (s, 1H), 7.2-6.6 (m, 4H), 3.8

10 (s, 3H), 3.6-1.8 (m, 22H), 1.0 (t, 3H).

MS (EI) m/z = 395.2 (M⁺).


EXAMPLE 32

(±)-trans-2-Dimethylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-

15 4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

0.5 g (1.25 mmol) of (±)-trans-2-dimethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]

isoquinoline were treated with 0.725 ml (7.5 mmol) of boron tribromide as described in example 2. The crude product was dissolved in MeOH and the solution brought to acidic pH with HCl/Et₂O. The solvent was evaporated *in vacuo* and the solid crystallized from EtOH, yielding 0.15 g of the title compound. M.p. = 305 °C dec.



I.R. (KBr): 3160, 1600, 1580 cm⁻¹

25 N.M.R. 300 MHz (DMSO-d₆): δ 10.4 (s, 1H), 10.2 (bs, 1H), 9.3 (s, 1H), 7.2-6.5 (m, 4H), 3.7-2.0 (m, 22H), 1.2 (t, 3H).

MS (TSP) m/z = 382.0 (M⁺).


EXAMPLE 33

30 (-)-trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

1.9 g (5.87 mmol) of (-)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride (Int. Pat. Appl. WO

35 93/01186), 4.61 g (17.61 mmol) of N,N-diethyl-2-phenylhydrazone-3-oxobutyramide, 1.45 g (17.61 mmol) of CH₃COONa, 1.9 g (29.35 mmol) of zinc dust and 15 ml of glacial acetic acid were treated as described in example 1. The residue was purified by flash chromatography ((i-Pr)₂O/MeOH/conc. NH₄OH 75:25:0.5). The resulting solid was dissolved in acetone and the solution brought to

acidic pH with HCl/Et₂O. The solvent was evaporated *in vacuo* and the solid triturated with Et₂O, yielding 2.3 g of the title compound. M.p. = 201-205 °C.



I.R. (KBr) : 3400, 3200, 2920, 1600 cm⁻¹

5 N.M.R. 300 MHz (DMSO-d₆) : δ 10.7 (bs, 1H), 10.4 (s, 1H), 7.3-6.7 (m, 4H), 3.7 (s, 3H), 3.6-2.5 (m, 17H), 1.8 (s, 3H), 1.2-1.0 (m, 9H)
 $[\alpha]^{20}_D = -20.32$ (c = 1, MeOH).

The I.R. and N.M.R. spectra were identical to those obtained for the racemate.

10

EXAMPLE 34

(-) trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

15 2.3 g (5.0 mmol) of (-)-trans-2-diethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride were treated with 2.9 ml (30 mmol) of boron tribromide as described in example 2. The crude product was dissolved in MeOH and the solution brought to acidic pH with HCl/Et₂O. The precipitate was filtered and crystallized from a mixture of

20 acetone/MeOH = 9/1, yielding 0.37g of the title compound. M.p.= 239-241°C.



I.R. (KBr) : 3200, 2980, 2940, 1600 cm⁻¹

N.M.R. 300 MHz (DMSO-d₆) : δ 10.4 (s, 1H), 7.3-6.7 (m, 4H), 3.6-2.5 (m, 17H), 1.8 (s, 3H), 1.2-1.0 (m, 9H)

25 MS (EI) m/z = 409.3 (M⁺).

$[\alpha]^{20}_D = -57.94$ (c = 1, MeOH).

The I.R. and N.M.R. spectra were identical to those obtained for the racemate.

30

EXAMPLE 35

(+) trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

1.9 g (5.87 mmol) of (+)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-35 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride (Int. Pat. Appl. WO 93/01186), 4.61 g (17.61 mmol) of N,N-diethyl-2-phenylhydrazone-3-oxobutyramide, 1.45 g (17.61 mmol) of CH₃COONa, 1.9 g (29.35 mmol) of zinc dust and 15 ml of glacial acetic acid were treated as described in example 1. The residue was purified by flash chromatography ((i-Pr)₂O/MeOH/conc. NH₄OH

75:25:0.5). The resulting solid was dissolved in acetone and the solution brought to acidic pH with HCl/Et₂O. The solvent was evaporated *in vacuo* and the solid triturated with Et₂O, yielding 2.0 g of the title compound. M.p. = 200-204 °C
 $C_{26}H_{37}N_3O_2 \cdot HCl$

5 I.R. (KBr) : 3400, 3200, 2920, 1600 cm⁻¹
 N.M.R. 300 MHz (DMSO-d₆) : δ 10.7 (bs, 1H), 10.4 (s, 1H), 7.3-6.7 (m, 4H), 3.7 (s, 3H), 3.6-2.5 (m, 17H), 1.8 (s, 3H), 1.2-1.0 (m, 9H)
 $[\alpha]^{20}_D = +20.65$ (c = 1, MeOH).

10 The I.R. and N.M.R. spectra were identical to those obtained for the racemate.

EXAMPLE 36

(+)-trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

15 2.0 g (4.3 mmol) of (+)-trans-2-diethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride were treated with 2.5 ml (25.8 mmol) of boron tribromide as described in example 2. The crude product was dissolved in MeOH and the solution brought to acidic pH with
 20 HCl/Et₂O. The precipitate was filtered and crystallized from a mixture of acetone/MeOH = 9/1, yielding 0.28 g of the title compound. M.p. = 239-240 °C.
 $C_{25}H_{35}N_3O_2 \cdot HCl$
 I.R. (KBr) : 3200, 2980, 2940, 1600 cm⁻¹
 N.M.R. 300 MHz (DMSO-d₆) : δ 10.6 (bs, 1H), 10.4 (s, 1H), 7.3-6.7 (m, 4H), 3.6-2.5 (m, 17H), 1.8 (s, 3H), 1.2-1.0 (m, 9H)
 25 MS (EI) m/z = 409.2 (M⁺).
 $[\alpha]^{20}_D = +57.49$ (c = 1, MeOH).

The I.R. and N.M.R. spectra were identical to those obtained for the racemate.

30

EXAMPLE 37

(±)-trans-2-Diethylaminocarbonyl-6-(2-furylmethyl)-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride

35 1.3 g (3.3 mmol) of (±)-trans-2-diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline, 0.28 ml (4.95 mmol) of acetic acid, 0.33 ml (3.96 mmol) of 2-furaldehyde were dissolved in 50 ml of MeOH under nitrogen atmosphere. 0.415 g (6.6 mmol) of sodium cyanoborohydride were added and the solution stirred for 15 h. Additional acetic acid

(0.1 ml), 2-furaldehyde (0.3 ml) and sodium cyanoborohydride (0.2 g) were added. After two hours of stirring the reaction mixture was cooled to 0 °C and 50 ml of 5N hydrochloric acid were added. The solvent was removed *in vacuo*, the aqueous solution was extracted with Et₂O, the pH was adjusted to 8 with 20% NaOH and then extracted with AcOEt. The organic layer was dried over Na₂SO₄ and the solvent was removed *in vacuo*. The crude product was dissolved in acetone/MeOH and the solution brought to acidic pH with HCl/Et₂O. The precipitate was filtered, yielding 1.7 g of the title compound. M.p. = 105 °C dec.

5 **C₂₉H₃₇N₃O₃·HCl**
 10 I.R. (KBr) : 3400, 3200, 2940, 1600 cm⁻¹
 N.M.R. 300 MHz (DMSO-d₆) : δ 10.4 (s, 1H), 7.8-6.4 (m, 7H), 4.2 (s, 2H), 3.8 (s, 3H), 3.6-1.8 (m, 18H), 1.2-1.0 (m, 6H)
 MS (EI) m/z = 475 (M⁺).

15 **EXAMPLE 38**

(±)-trans-2-Diethylaminocarbonyl-6-(2-furylmethyl)-8a-(3-hydroxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline


1.7 g (3.32 mmol) of (±)-trans-2-dimethylaminocarbonyl-6-(2-furylmethyl)-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride were treated with 1.86 ml (19.9 mmol) of boron tribromide as described in example 2. The residue was purified by flash chromatography (EtOAc/MeOH/conc.NH₄OH 95:5:0.5). The solid was triturated with acetone, yielding 0.07 g of the title compound. M.p. = 215-216 °C dec.

25 **C₂₈H₃₅N₃O₃**
 I.R. (KBr): 3340, 2930, 2900, 1590 cm⁻¹
 N.M.R. 300 MHz (DMSO-d₆): δ 10.4 (s, 1H), 9.2 (s, 1H), 7.5 (s, 2H), 7.1-6.2 (m, 6H), 3.5-1.8 (m, 19H), 1.0 (t, 6H).
 MS (EI) m/z = 461.1 (M⁺).

30 **EXAMPLE 39**

(±)-trans-2-Diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline

35 1.6 g (5.7 mmol) of (±)-trans-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 6.0 g (22.8 mmol) of N,N-diethyl-2-phenylhydrazone-3-oxobutyramide, 1.9 g (22.8 mmol) of CH₃COONa, 2.2 g (34.2 mmol) of zinc dust and 30 ml of glacial acetic acid were treated as described in example 1, yielding 1.3 g of the title compound. M.p. = 197-199 °C.




I.R. (KBr) : 3270, 2915, 1605 cm^{-1}

EXAMPLE 40

5 (±)-trans-6-Butyl-2-diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline

0.2 g (0.57 mmol) of (±)-trans-2-butyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 0.45 g (1.71 mmol) of 10 N,N-diethyl-2-phenylhydrazone-3-oxobutyramide, 0.14 g (1.71 mmol) of CH_3COONa , 0.22 g (3.42 mmol) of zinc dust and 5 ml of glacial acetic acid were treated as described in example 1, yielding 0.15 g of the title compound. M.p. = 134 °C dec.



15 I.R. (KBr) (hydrochloride) : 3200, 2960, 2925, 1630, 1600 cm^{-1}

EXAMPLE 41

(±)-trans-6-Butyl-2-diethylaminocarbonyl-8a-(3-hydroxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline

20 0.15 g (0.31 mmol) of (±)-trans-6-butyl-2-diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline were treated with 0.174 ml (1.86 mmol) of boron tribromide as described in example 2, yielding 0.06 g of the title compound. M.p. = 228-229 °C



I.R. (KBr): 3330, 2920, 1590 cm^{-1}

EXAMPLE 42

(±)-trans-7-Ethyl-4a-(3-methoxyphenyl)-1-methyl-4,4a,5,6,7,8,8a,9-octahydro-2-phenyl-1H-imidazo[4,5-g]isoquinoline

A solution of 0.46 g (2.98 mmol) of N-methylbenzimidoyl chloride (*J. Am. Chem. Soc.*, 1962, 84, 769) in 12 ml of THF was cooled to -78 °C under nitrogen atmosphere and 0.73 ml (5.21 mmol) of triethylamine were added. After 30 min a 35 solution of 0.45 g (1.49 mmol) of (±)-trans-2-ethyl-6-hydroxyimino-4a-(3-methoxyphenyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline in 3 ml of THF was added. The reaction mixture was allowed to warm to room temperature and then refluxed for 5 h. Water was added and the mixture was extracted with CH_2Cl_2 . The organic layer was washed with brine and dried. The solvent was removed *in vacuo*

and the resulting product was dissolved in 25 ml of toluene, 0.99 g of p-toluenesulphonic acid were added and the reaction mixture was heated to reflux in a Dean-Stark apparatus for 6 h. The solvent was removed *in vacuo*, the residue was taken up in water, the pH adjusted to 10 with 1N NaOH. The aqueous layer was extracted with CH₂Cl₂, the organic layer was dried and the solvent was removed *in vacuo*. The crude product was purified by flash chromatography (EtOAc/MeOH/conc.NH₄OH 85:15:2) yielding 0.276 g of the title compound. M.p. = 146-150 °C.

5 C₂₆H₃₁N₃O

10 I.R. (KBr): 2920, 1600, 1580 cm⁻¹

N.M.R. 300 MHz (DMSO-d₆): δ 7.6-6.6 (m, 9H), 3.8 (s, 3H), 3.5 (s, 3H), 3.0-1.6 (m, 13H), 1.0 (t, 3H).

MS (EI) m/z = 401.2 (M⁺).

15 EXAMPLE 43

(±)-trans-7-Ethyl-4a-(3-hydroxyphenyl)-1-methyl-4,4a,5,6,7,8,8a,9-octahydro-2-phenyl-1H-imidazo[4,5-g]isoquinoline

0.27 g (0.67 mmol) of (±)-trans-7-ethyl-4a-(3-methoxyphenyl)-1-methyl-

20 4,4a,5,6,7,8,8a,9-octahydro-2-phenyl-1H-imidazo[4,5-g]isoquinoline were treated with 0.38 ml (4.02 mmol) of boron tribromide as described in example 2. The residue was purified by flash chromatography (EtOAc/MeOH/conc.NH₄OH 80:20:2). The resulting solid was crystallized from acetone, yielding 0.13 g of the title compound. M.p. = 249-251 °C.

25 C₂₅H₂₉N₃O

I.R. (KBr): 3400, 2940, 1595, 1450 cm⁻¹

N.M.R. 300 MHz (DMSO-d₆): δ 9.1 (s, 1H), 7.8-6.4 (m, 9H), 3.5 (s, 3H), 3.0-1.6 (m, 13H), 1.0 (t, 3H).

MS (EI) m/z = 387.2 (M⁺).

30

EXAMPLE 44

(±)-trans-6-Ethyl-8a-(3-methoxyphenyl)-3-methyl-2-pyrrolidinocarbonyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

35 1 g (3.1 mmol) of (±)-trans-2-ethyl-4a-(3-methoxyphenyl)-6-oxo-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline hydrochloride, 2.4 g (9.3 mmol) of 1-(2-phenylhydrazono-3-oxobutyryl)pyrrolidine, 0.76 g (9.3 mmol) of CH₃COONa, 2.4 g (37.2 mmol) of zinc dust and 10 ml of glacial acetic acid were treated as described in example 1. The crude product was purified by flash chromatography

(EtOAc/MeOH/conc.NH₄OH 80:20:0.5). The residue was dissolved in acetone and the solution brought to acidic pH with HCl/Et₂O. The precipitate was filtered, yielding 0.63 g of the title compound. M.p. = 127-131 °C.




5 I.R. (KBr): 3280, 2940, 1610, 1580 cm⁻¹.

EXAMPLE 45

(±)-trans-6-Ethyl-8a-(3-hydroxyphenyl)-3-methyl-2-pyrrolidinocarbonyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline

10 0.63 g (1.37 mmol) of (±)-trans-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-2-pyrrolidinocarbonyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline were treated with 0.77 ml (8.22 mmol) of boron tribromide as described in example 2. The residue was purified by flash chromatography (EtOAc/MeOH/conc.NH₄OH 80:20:0.5). The resulting solid was triturated with Et₂O, yielding 0.13 g of the title compound. M.p. = 224-226 °C.



15 I.R. (KBr): 3400, 2940, 1595, 1450 cm⁻¹

EXAMPLE 46

(±)-trans-2-Diisopropylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-6-propyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride

20 0.34 g (0.74 mmol) of (±)-trans-2-diisopropylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride, 0.095 g (0.78 mmol) of propyl bromide, 0.204 g (1.48 mmol) of potassium carbonate and a catalytic amount of potassium iodide in 5 ml of dimethylformamide were treated as described in example 29. The residue was dissolved in Et₂O and the solution brought to acidic pH with HCl/Et₂O. The precipitate was filtered yielding 0.22 g of the title compound. M.p. = 150 °C dec.



25 I.R. (KBr) : 3400, 3200, 2915, 2580, 1600 cm⁻¹

EXAMPLE 47

30 (±)-trans-2-Diisopropylaminocarbonyl-8a-(3-hydroxyphenyl)-3-methyl-6-propyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride


35 0.22 g (0.44 mmol) of (±)-trans-2-diisopropylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-6-propyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline

hydrochloride were treated with 0.25 ml (2.64 mmol) of boron tribromide as described in example 2. The residue was purified by flash chromatography (EtOAc/MeOH/conc.NH₄OH 80:20:0.5). The residue was dissolved in acetone and the solution brought to acidic pH with HCl/Et₂O. The precipitate was filtered 5 yielding 0.055 g of the title compound. M.p. = 240-243 °C.



I.R. (KBr): 3400, 2940, 1595, 1450 cm⁻¹


CHEMICAL TABLE



I

Ex. n.	R	R1	R2	R3	R4	R5		*	Molecular formula	M.P. °C
1	Et	m-OMe	H	H	CONEt ₂	Me		(±)	C ₂₆ H ₃₇ N ₃ O ₂	247 dec. (as ·HCl)
2	Et	m-OH	H	H	CONEt ₂	Me		(±)	C ₂₅ H ₃₅ N ₃ O ₂	221-223
3	Et	m-OMe	H	H	COOEt	Me		(±)	C ₂₄ H ₃₂ N ₂ O ₃	-----
4	Et	m-OH	H	H	COOEt	Me		(±)	C ₂₃ H ₃₀ N ₂ O ₃ ·0.5 H ₂ O	195-197
5	Et	m-OMe	H	H	CON-n-Pr ₂	Me		(±)	C ₂₈ H ₄₁ N ₃ O ₂ ·HCl	250 dec.
6	Et	m-OH	H	H	CON-n-Pr ₂	Me		(±)	C ₂₇ H ₃₉ N ₃ O ₂	151-153
7	Et	m-OMe	H	H	COO-i-Bu	Me		(±)	C ₂₆ H ₃₆ N ₂ O ₃ ·HCl	230 dec.
8	Et	m-OH	H	H	COO-i-Bu	Me		(±)	C ₂₅ H ₃₄ N ₂ O ₃	196-198
9	Me	m-OMe	H	H	CONEt ₂	Me		(±)	C ₂₅ H ₃₅ N ₃ O ₂	250 dec. (as ·HCl)
10	Me	m-OH	H	H	CONEt ₂	Me		(±)	C ₂₄ H ₃₃ N ₃ O ₂ ·HCl	>250


CHEMICAL TABLE (continued)



I

Ex. n.	R	R ₁	R ₂	R ₃	R ₄	R ₅		*	Molecular formula	M.P. °C
11	Me	m-OMe	H	H	CONEt ₂	Me		(±)	C ₂₅ H ₃₅ N ₃ O ₂	153-155
12	Me	m-OH	H	H	CONEt ₂	Me		(±)	C ₂₄ H ₃₃ N ₃ O ₂	235-238
13	Me	m-OMe	H	H	CONHCH ₂ Ph	Me		(±)	C ₂₈ H ₃₃ N ₃ O ₂	162-164
14	Me	m-OH	H	H	CONHCH ₂ Ph	Me		(±)	C ₂₇ H ₃₁ N ₃ O ₂ ·HCl	297-299
15	Me	m-OMe	H	H	CON(-CH ₂ -) ₄	Me		(±)	C ₂₅ H ₃₃ N ₃ O ₂	171-173
16	Me	m-OH	H	H	CON(-CH ₂ -) ₄	Me		(±)	C ₂₄ H ₃₁ N ₃ O ₂ ·HCl	230-233
17	Et	m-OMe	H	H	CONHPh	Me		(±)	C ₂₈ H ₃₃ N ₃ O ₂	178-180
18	Et	m-OH	H	H	CONHPh	Me		(±)	C ₂₇ H ₃₁ N ₃ O ₂ ·HCl	271-272
19	Et	m-OMe	H	H	CSNEt ₂	Me		(±)	C ₂₆ H ₃₇ N ₃ OS	156-158
20	Et	m-OH	H	H	CSNEt ₂	Me		(±)	C ₂₅ H ₃₅ N ₃ OS	243-245


CHEMICAL TABLE (continued)



I

Ex. n.	R	R ₁	R ₂	R ₃	R ₄	R ₅		*	Molecular formula	M.P. °C
21	CPM	m-OMe	H	H	CONEt ₂	Me		(±)	C ₂₈ H ₃₉ N ₃ O ₂ ·HCl	190-195
22	CPM	m-OH	H	H	CONEt ₂	Me		(±)	C ₂₇ H ₃₇ N ₃ O ₂ ·HCl	270-272 dec
23	Et	m-OMe	H	H	CON(i-Pr) ₂	Me		(±)	C ₂₈ H ₄₁ N ₃ O ₂	oil
24	Et	m-OH	H	H	CON(i-Pr) ₂	Me		(±)	C ₂₇ H ₃₉ N ₃ O ₂ ·HCl	263-265
25	Et	m-OMe	H	H	CONH ₂	Me		(±)	C ₂₂ H ₂₉ N ₃ O ₂	176-178
26	Et	m-OH	H	H	CONH ₂	Me		(±)	C ₂₁ H ₂₇ N ₃ O ₂ ·HCl	270-273
27	Et	m-OMe	H	H	COOEt	CF ₃		(±)	C ₂₄ H ₂₉ F ₃ N ₂ O ₃	209-211
28	Et	m-OH	H	H	COOEt	CF ₃		(±)	C ₂₃ H ₂₇ F ₃ N ₂ O ₃ ·HCl	275-278
29	n-Pr	m-OMe	H	H	CONEt ₂	Me		(±)	C ₂₇ H ₃₉ N ₃ O ₂ ·HCl	102-106 dec.
30	n-Pr	m-OH	H	H	CONEt ₂	Me		(±)	C ₂₆ H ₃₇ N ₃ O ₂ ·HCl	236-238


CHEMICAL TABLE (continued)



I

Ex. n.	R	R ₁	R ₂	R ₃	R ₄	R ₅		*	Molecular formula	M.P. °C
31	Et	m-OMe	H	H	CONMe ₂	Me		(±)	C ₂₄ H ₃₃ N ₃ O ₂	151-153
32	Et	m-OH	H	H	CONMe ₂	Me		(±)	C ₂₃ H ₃₁ N ₃ O ₂ ·HCl	305 dec.
33	Et	m-OMe	H	H	CONEt ₂	Me		(-)	C ₂₆ H ₃₇ N ₃ O ₂ ·HCl	201-205
34	Et	m-OH	H	H	CONEt ₂	Me		(-)	C ₂₅ H ₃₅ N ₃ O ₂ ·HCl	239-241
35	Et	m-OMe	H	H	CONEt ₂	Me		(+)	C ₂₆ H ₃₇ N ₃ O ₂ ·HCl	200-204
36	Et	m-OH	H	H	CONEt ₂	Me		(+)	C ₂₅ H ₃₅ N ₃ O ₂ ·HCl	239-240
37	2-furyl methyl	m-OMe	H	H	CONEt ₂	Me		(±)	C ₂₉ H ₃₇ N ₃ O ₃ ·HCl	105 dec.
38	2-furyl methyl	m-OH	H	H	CONEt ₂	Me		(±)	C ₂₈ H ₃₅ N ₃ O ₃	215-216 dec.
39	H	m-OMe	H	H	CONEt ₂	Me		(±)	C ₂₄ H ₃₃ N ₃ O ₂	197-199
40	n-Bu	m-OMe	H	H	CONEt ₂	Me		(±)	C ₂₈ H ₄₁ N ₃ O ₂	134 dec.

CHEMICAL TABLE (continued)



I

Ex. n.	R	R ₁	R ₂	R ₃	R ₄	R ₅		*	Molecular formula	M.P. °C
41	n-Bu	m-OH	H	H	CONEt ₂	Me		(±)	C ₂₇ H ₃₉ N ₃ O ₂	228-229
42	Et	m-OMe	H	H	Ph	Me		(±)	C ₂₆ H ₃₁ N ₃ O	146-150
43	Et	m-OH	H	H	Ph	Me		(±)	C ₂₅ H ₂₉ N ₃ O	249-251
44	Et	m-OMe	H	H	CON(-CH ₂) ₄	Me		(±)	C ₂₆ H ₃₅ N ₃ O ₂ ·HCl	127-131
45	Et	m-OH	H	H	CON(-CH ₂) ₄	Me		(±)	C ₂₅ H ₃₃ N ₃ O ₂	224-226
46	n-Pr	m-OMe	H	H	CON(i-Pr) ₂	Me		(±)	C ₂₉ H ₄₃ N ₃ O ₂ ·HCl	150 dec.
47	n-Pr	m-OH	H	H	CON(i-Pr) ₂	Me		(±)	C ₂₈ H ₄₁ N ₃ O ₂ ·HCl	240-243

PHARMACOLOGICAL METHODS AND RESULTS

OPIOID RADIOLIGAND BINDING ASSAYS

Mouse brain membranes were prepared as described by Kosterlitz (*Br. J. Pharmacol.*, 1981, 73, 939.). The binding of the preferential *delta* ligand [³H]-[D-Ala²,D-Leu⁵]-enkephalin (DADLE) was evaluated at its K_D concentration (1.3 nM) in presence of 40 nM of the unlabelled *mu* ligand [D-Ala², MePhe⁴, Gly-ol⁵]-enkephalin (DAMGO). The binding of the *mu* ligand [³H]-DAMGO (*Eur. J. Pharmacol.*, 1989, 166, 213) and of the *kappa* ligand [³H]-U69593 (*Excerpta Medica*, 1990, 211) were carried out at 0.5 nM. The non-specific binding was determined in presence of naloxone (10 μ M) for all tritiated ligands. Binding data were expressed as percentage of inhibition and fitted the following equation: $f(x) = 100 \cdot X / (IC_{50} + X)$ where X are cold drug concentration values. The IC_{50} obtained were used to calculate the inhibitory constants (K_i) accordingly to the Cheng and Prusoff relation (*Biochem. Pharmacol.*, 1973, 22, 3099).

MOUSE VAS DEFERENS (MVD) BIOASSAYS

Vasa deferentia were obtained from CD-1 mice and were suspended in a Mg^{2+} -free Krebs buffer at 37 °C. For the *delta* agonist/antagonist studies, the tissues were electrically stimulated with pulse trains having the following parameters: train duration 50 ms, stimulus duration 2 ms, frequency of stimuli 50 Hz, maximal voltage 60-70 V, train frequency 0.1 Hz. Concentration response curves for each compounds were constructed cumulatively. Linear regression analysis and IC_{50} concentrations were evaluated according to Tallarida and Murray (*Manual of Pharmacological Calculations*, Springer Verlag NY, 1981).


The most potent compounds described in the present invention showed affinities for the *delta* receptor ranging from 0.5 to 200 nM with *delta* selectivity ranging from 30 to 1500 times in respect to the other opioid receptor types. These compounds displayed also potent *delta* agonist and antagonist properties in the MVD preparation. Selective *delta* agonists (antagonised by the selective *delta* antagonist naltrindole) displayed IC_{50} s ranging from 1 to 500 nM. For example, compound of example 34 shows a $Ki_{delta} = 0.73$ nM, $Ki_{mu}/Ki_{delta} = 110$ and $Ki_{kappa}/Ki_{delta} = 1105$ and an $IC_{50} = 26$ nM in the MVD preparation. Selective *delta* antagonists showed K_e s against DADLE ranging from 1 to 50 nM. For example, compound of example 10 shows a $Ki_{delta} = 2.15$ nM, $Ki_{mu}/Ki_{delta} = 45$ and $Ki_{kappa}/Ki_{delta} = 403$ and a $K_e = 7$ nM against DADLE in the MVD preparation.

Mouse abdominal constriction (MAC) (*Proc. Soc. Exp. Biol. Med.*, 1957, 95, 729),

mouse tail-flick (MTF) (*J. Pharm. Exp. Ther.*, 1941, 72, 74) and mouse tail-flick warm water (MTF-WW) (*Life Sci.*, 1986, 39, 1795) were adopted to evaluate the antinociceptive efficacy of the compounds of the present invention.

Claims:

1. A compound, or solvate or salt thereof, of formula (I):




wherein:

R is hydrogen or a straight or branched C₁-C₅ alkyl, C₃-C₇ cycloalkyl, C₄-C₆ cycloalkylalkyl, C₃-C₅ alkenyl, aryl, aralkyl or furan-2-yl-alkyl;


R₁ and R₂, which can be the same or different, are each hydrogen, hydroxy, C₁-C₃ alkoxy, halogen, SH, C₁-C₄-alkylthio, NHR₆, NR₆R₇, NHCOR₆, NHSO₂R₆, wherein R₆ and R₇, which are the same or different, are hydrogen or C₁-C₆ alkyl;

10 R₃ is hydrogen, hydroxy or C₁-C₃ alkoxy;




15 (R₁ and R₂ having the meanings defined above) or a -C(Z)-R₈ group, in which Z is oxygen or sulphur, and R₈ is C₁-C₁₈-alkyl, C₁-C₁₈-alkoxy or NR₉R₁₀, wherein R₉ and R₁₀, which may be the same or different, are hydrogen, straight or branched C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₆ cycloalkylalkyl, C₃-C₆ alkenyl, aryl, aralkyl or an optionally substituted heterocyclic ring or, taken together with the nitrogen atom which they are linked to, they form an alkylene chain having from 2 to 5 carbon atoms, optionally interrupted by an oxygen or nitrogen atom;

20 or R₄ is a group



25 in which R₁₁ and R₁₂ are the same as R₉ and R₁₀ respectively, and Z is as defined above;

R₅ is hydrogen, C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, trifluoromethyl or is a



(R₁ and R₂ having the meanings defined above);
 n is zero or 1;
 if n is zero, one of X or Y is NH, oxygen or sulphur, and the other is NH, CH or a
 5 R₄- or R₅-substituted carbon atom; if n is 1, then X and Y are both nitrogen, or one
 of them is nitrogen and the other is CH or a R₄- or R₅-substituted carbon atom.

2. A compound according to claim 1 in which R is methyl, ethyl,
 cyclopropylmethyl, propyl, 2-phenylethyl or 2-furylmethyl.

10 3. A compound according to claim 1 or 2 in which each of R₁ and R₂ is
 hydrogen, hydroxy, methoxy, chlorine, bromine, fluorine, SH, methylthio, amino,
 methylamino, ethylamino, dimethylamino, diethylamino, diisopropylamino,
 methylisopropylamino, acetylamino or sulfonylamino, at any position of the ring.

15 4. A compound according to any one of claims 1 to 3 in which R₅ is hydrogen,
 methyl, ethyl, propyl, butyl, hexyl, octyl, decyl, dodecyl, octadecyl, allyl,
 trifluoromethyl or phenyl.

20 5. A compound according to any one of claims 1 to 4 in which R₄ is
 ethoxycarbonyl, i-butyloxycarbonyl, aminocarbonyl, dimethylaminocarbonyl,
 diethylaminocarbonyl, di-n-propylaminocarbonyl, di-i-propylaminocarbonyl,
 pyrrolidinocarbonyl, benzylaminocarbonyl, phenylaminocarbonyl,
 morpholinocarbonyl, N-ethyl-N-i-isopropylaminocarbonyl,
 25 diethylaminothiocarbonyl, or phenyl.

6. A compound selected from:

(±)-trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-
 30 4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

(±)-trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-
 4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

35 (±)-trans-6-Ethyl-2-ethoxycarbonyl-3-methyl-8a-(3-methoxyphenyl)-

4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

(\pm)-trans-6-Ethyl-2-ethoxycarbonyl-8a-(3-hydroxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

5 (\pm)-trans-Dipropylaminocarbonyl-6-ethyl-3-methyl-8a-(3-methoxyphenyl)-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

(\pm)-trans-Dipropylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-
10 4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

(\pm)-trans-2-(i-Butoxycarbonyl)-6-ethyl-3-methyl-8a-(3-methoxyphenyl)-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

15 (\pm)-trans-2-(i-Butoxycarbonyl)-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

(\pm)-trans-2-Diethylaminocarbonyl-3,6-dimethyl-8a-(3-methoxyphenyl)-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

20 (\pm)-trans-2-Diethylaminocarbonyl-3,6-dimethyl-8a-(3-hydroxyphenyl)-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

(\pm)-trans-2-Diethylaminocarbonyl-3,7-dimethyl-4a-(3-methoxyphenyl)-
25 4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[3,2-g]isoquinoline;

(\pm)-trans-2-Diethylaminocarbonyl-3,7-dimethyl-4a-(3-hydroxyphenyl)-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[3,2-g]isoquinoline;

30 (\pm)-trans-2-Benzylaminocarbonyl-3,6-dimethyl-8a-(3-methoxyphenyl)-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

(\pm)-trans-2-Benzylaminocarbonyl-3,6-dimethyl-8a-(3-hydroxyphenyl)-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

35 (\pm)-trans-3,6-Dimethyl-8a-(3-methoxyphenyl)-2-pyrrolidinocarbonyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

(\pm)-trans-3,6-Dimethyl-8a-(3-hydroxyphenyl)-2-pyrrolidinocarbonyl-

4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

(\pm)-trans-6-Ethyl-3-methyl-8a-(3-methoxyphenyl)-2-phenylaminocarbonyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

5

(\pm)-trans-6-Ethyl-8a-(3-hydroxyphenyl)-3-methyl-2-phenylaminocarbonyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

(\pm)-trans-2-Diethylaminothiocarbonyl-6-ethyl-3-methyl-8a-(3-methoxyphenyl)-

10 4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

(\pm)-trans-2-Diethylaminothiocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-

4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

15 (\pm)-trans-6-Cyclopropylmethyl-2-diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-
methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride;

(\pm)-trans-6-Cyclopropylmethyl-2-diethylaminocarbonyl-8a-(3-hydroxyphenyl)-3-
methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride;

20

(\pm)-trans-2-Diisopropylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline;

(\pm)-trans-2-Diisopropylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-

25 4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

(\pm)-trans-2-Aminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-

4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline;

30 (\pm)-trans-2-Aminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride;

(\pm)-trans-6-Ethyl-2-ethoxycarbonyl-8a-(3-methoxyphenyl)-4,4a,5,6,7,8,8a,9-
octahydro-3-trifluoromethyl-1H-pyrrolo[2,3-g]isoquinoline;

35

(\pm)-trans-6-Ethyl-2-ethoxycarbonyl-8a-(3-hydroxyphenyl)-4,4a,5,6,7,8,8a,9-
octahydro-3-trifluoromethyl-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

(\pm)-trans-2-Diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-6-propyl-

4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

(\pm)-trans-2-Diethylaminocarbonyl-8a-(3-hydroxyphenyl)-3-methyl-6-propyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

5 (\pm)-trans-2-Dimethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline;

10 (\pm)-trans-2-Dimethylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

(-)-trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

15 (-)-trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

(+)-trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-methoxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

20 (+)-trans-2-Diethylaminocarbonyl-6-ethyl-8a-(3-hydroxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

(\pm)-trans-2-Diethylaminocarbonyl-6-(2-furylmethyl)-8a-(3-methoxyphenyl)-3-
methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline hydrochloride;

25 (\pm)-trans-2-Diethylaminocarbonyl-6-(2-furylmethyl)-8a-(3-hydroxyphenyl)-3-
methyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g] isoquinoline;

30 (\pm)-trans-2-Diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-4,4a,5,6,7,8,8a-
octahydro-1H-pyrrolo[2,3-g]isoquinoline;

(\pm)-trans-6-Butyl-2-diethylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

35 (\pm)-trans-6-Butyl-2-diethylaminocarbonyl-8a-(3-hydroxyphenyl)-3-methyl-
4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

(\pm)-trans-7-Ethyl-4a-(3-methoxyphenyl)-1-methyl-4,4a,5,6,7,8,8a,9-octahydro-2-

phenyl-1H-imidazo[4,5-g]isoquinoline;

(\pm)-trans-7-Ethyl-4a-(3-hydroxyphenyl)-1-methyl-4,4a,5,6,7,8,8a,9-octahydro-2-phenyl-1H-imidazo[4,5-g]isoquinoline;

5

(\pm)-trans-6-Ethyl-8a-(3-methoxyphenyl)-3-methyl-2-pyrrolidinocarbonyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride;

10 (\pm)-trans-6-Ethyl-8a-(3-hydroxyphenyl)-3-methyl-2-pyrrolidinocarbonyl-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline;

(\pm)-trans-2-Diisopropylaminocarbonyl-8a-(3-methoxyphenyl)-3-methyl-6-propyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride, and

15 (\pm)-trans-2-Diisopropylaminocarbonyl-8a-(3-hydroxyphenyl)-3-methyl-6-propyl-4,4a,5,6,7,8,8a-octahydro-1H-pyrrolo[2,3-g]isoquinoline hydrochloride.

7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier.

20

8. A compound according to any one of claims 1 to 6 for use as an active therapeutic substance.

25

9. A compound according to any one of claims 1 to 6 for use in the treatment of pain or as an immunomodulating and/or cardiovascular agent.

10. The use of a compound according to any one of claims 1 to 6 in the manufacture of a medicament for the treatment of pain or as an immunomodulating and/or cardiovascular agent.

30

11. A method for the treatment and/or prophylaxis of pain and of rejection of transplants and skin grafts in mammals particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of a compound according to any one of claims 1 to 6.

35

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/EP 94/02325

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D471/04 A61K31/435 C07D498/04 C07D491/048 C07D513/04
 C07D495/04 // (C07D471/04, 221:00, 209:00), (C07D471/04, 235:00,
 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,93 01186 (ZAMBELETTI) 21 January 1993 cited in the application see page 1, line 26 - line 29; claims 1,11 -----	1,10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

1

Date of the actual completion of the international search

Date of mailing of the international search report

10 November 1994

21.11.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentstaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Alfar Faus, I

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 94/02325

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 11 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 94/02325

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9301186	21-01-93	AU-A-	2194892	11-02-93